Antibody-conjugated drug and use thereof
By designing a new antibody-conjugated drug, using specific structural composition and toxin molecules to combine, the shortcomings of existing antibody-conjugated drugs in water solubility and safety are solved, and efficient targeting and safe killing of tumor cells is achieved. , improves the overall efficacy and safety of the drug.
Patent Information
- Application Number
- PCT/CN2024/080908
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-09
- Filing Date
- 2024-03-11
- Publication Date
- 2024-11-14
AI Technical Summary
Existing antibody-conjugated drugs have insufficient water solubility and safety, resulting in the restrictive bystander effect of compound design in some examples, targeting initial degradation products in tumor cells has a strong bystander effect, which may be in contrast to the Neighbors kill, limiting the safety and effectiveness of the drug.
A novel antibody-coupled drug is designed, which includes a compound P-L-D, which improves the water solubility and coupling efficiency of the drug through specific structural composition. Using a strategy of binding hydrophilic groups and toxin molecules, the toxin molecule can be O Ristatin F derivatives or exitecan analogs form free thiol groups and couple them to antibodies through the reduction of inter-chain disulfide bonds, controlling the molecular weight of the drug and the average number of linkages (DAR values) of toxins to optimize drug performance.
It improves the water solubility and safety of the drug, reduces the side effects on normal cells, enhances the targeting and killing efficacy of tumor cells, and improves the overall efficacy and safety of the drug.
Smart Images

Figure CN2024080908_14112024_PF_FP_ABST
Abstract
Description
Antibody-drug conjugate and its use
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to Chinese patent application No. 202310519730.1 filed on May 9, 2023, the entire contents of which are incorporated herein by reference. Technical Field
[0003] The present application relates to the field of biomedicine, and in particular to an antibody-drug conjugate and its use. Background Art
[0004] In the past, tumor treatment was mainly based on chemotherapy drugs. Chemotherapy is the preferred systemic cancer treatment method using cytotoxic drugs. It mainly works by interfering with the cell cycle, delaying or completely preventing the reproduction of tumor cells. However, since chemotherapy drugs also indiscriminately kill normal cells, they can cause serious side effects.
[0005] Antibody-drug conjugates (ADCs) are therapeutic agents composed of antibodies targeting specific antigens and toxin molecules coupled via a linker. They combine the powerful killing effects of traditional small molecule chemotherapy with the tumor targeting properties of antibody drugs. This also means that compared with traditional chemotherapy drugs, antibody-drug conjugates can precisely bind to tumors and reduce the impact on normal cells (Mullard A, (2013) Nature Reviews Drug Discovery, 12:329-332; DiJoseph JF, Armellino DC, (2004) Blood, 103:1807-1814). Therefore, in terms of the targeted disease areas, ADC drugs are highly concentrated, mainly in the field of oncology.
[0006] In 2000, the first antibody-drug conjugate, Mylotarg (gemtuzumab ozogamicin, Wyeth Pharmaceuticals, Inc.), was approved by the U.S. FDA for the treatment of acute myeloid leukemia (Drugs of the Future (2000) 25(7):686; US4970198; US5-79233; US5585089; US5606040; US5693762; US5739116; US5767285; US5773001).
[0007] In August 2011, Adcetris (brentuximab vedotin, Seattle Genetics) passed the U.S. FDA fast-track review for the treatment of Hodgkin's lymphoma and relapsed anaplastic large cell lymphoma (Nat. Biotechnol (2003) 21(7):778-784; WO2004010957; WO2005001038; US7090843A; US7659241; WO2008025020). It is a new type of targeted ADC drug that directly targets CD30 on lymphoma cells, leading to endocytosis and inducing apoptosis. Both Mylotarg and Adcetris are targeted therapies for hematologic malignancies, which have a relatively simpler tissue structure than solid tumors. In February 2013, Kadcyla (ado-trastuzumab emtansine, T-DM1) received FDA approval for the treatment of patients with HER2-positive advanced and metastatic breast cancer that is resistant to trastuzumab (trade name: Herceptin) and paclitaxel (WO2005037992; US8088387). Kadcyla is the first ADC drug approved by the FDA for the treatment of solid tumors.
[0008] In December 2019, DS-8201a (Trastuzumab Deruxtecan, trade name: Enhertu) developed by Daiichi Sankyo was approved by the FDA in the United States for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received two or more HER2-targeted therapies. Enhertu consists of a topoisomerase I inhibitor payload (DXd) connected to a cleavable tetrapeptide linker. The linker is attached to a cysteine residue on the antibody, and the DAR of the ADC is approximately 8. In April 2020, Sacituzumab govitecan (trade name: Immunomedics Inc.) was approved by the FDA for the treatment of triple-negative breast cancer. It targets the tumor-associated calcium signaling 2 (TROP-2) receptor, which is often expressed at high levels in triple-negative breast cancer. The payload, SN-38, is a topoisomerase I inhibitor, linked to the antibody via a hydrolyzable linker (pH-sensitive linker) CL2A. It binds to the antibody via a cysteine residue and has a DAR of 7.6. Both camptothecin ADCs utilize a conjugation strategy with high DAR values.
[0009] As of December 2022, a total of 15 ADC drugs have been approved for marketing worldwide for the treatment of various cancers, including hematological malignancies and solid tumors. However, current ADC drugs often suffer from safety flaws such as poor water solubility and toxicity due to high DAR values. In some instances, the compound design has a restrictive bystander effect. The initial degradation products in the targeted tumor cells have a strong bystander effect and have transmembrane ability, which can kill adjacent cells. After further degradation to auristatin F, it no longer has transmembrane ability. This restrictive bystander effect improves the safety of the drug. Therefore, this field still needs to further optimize the molecular structure, improve the water solubility of the conjugated drug, increase the conjugation efficiency, and further improve safety on the basis of increased effectiveness.
[0010] Summary of the Invention
[0011] In the first aspect, the present application provides a compound of formula (I) or an isotope-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, PLD (I)
[0012] in,
[0013] P has the following structure:
[0014] m and n are each independently selected from any integer from 0 to 12;
[0015] X1 is selected from a bond, a C1-C6 alkylene group, an imino group, an ester group, an amide group, a carbonate group, a carbamate group, a sulfone group, a sulfonamide group, a ketone group, a urea group or a phosphate group;
[0016] X2 is selected from a bond, nitrogen, oxygen, sulfur, phosphorus, C1-C6 alkylene, imino, ester, amide, carbonate, carbamate, sulfone, sulfonamide, ketone, urea or phosphate;
[0017] L has the following structure:
[0018] n1 and n2 are each independently selected from any integer from 1 to 6;
[0019] R1 is selected from a hydrophilic group;
[0020] R2 and R3 are each independently selected from H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, or R2 and R3 together with the carbon atoms to which they are attached form a C3-C6 cycloalkyl, wherein one or more hydrogen atoms in the C1-C6 alkyl, C1-C6 haloalkyl or C3-C6 cycloalkyl are optionally substituted with halogen, hydroxy, cyano, amino, C1-C3 alkyl or phenyl;
[0021] R4 is selected from the R group in the α-amino acid general formula R-CH(NH2)COOH;
[0022] R5 is selected from a bond or -Y1-R6-Y2-, wherein Y1 is a bond, -NH- or -O-, Y2 is -NH- or -C=O-, and R6 is selected from -(CH2) z -、-(OCH2) z -、-(CH2O) z -、-(CH2CH2O) z -、-(OCH2CH2) z -, C3-C6 cycloalkyl or a covalently linked combination thereof, z is selected from any integer from 0 to 6; and
[0023] D is a toxin molecule or other equivalent.
[0024] In one embodiment of the present invention, the hydrophilic group may have at least three (e.g., three, four, five or six, etc.) ether bonds and / or hydroxyl groups composed of oxygen-containing groups (the molecular weight of the hydrophilic group is preferably between 100 and 500 Da, such as about 200 Da, 300 Da or 400 Da, etc.). More preferably, the hydrophilic group may have any one of the following structures:
[0025] In another embodiment of the present invention, R2 and R3 can be each independently selected from H, F, Cl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or R2 and R3 can be together with the carbon atoms to which they are attached to form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein one or more hydrogen atoms in the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl are optionally substituted with halogen, hydroxyl, cyano, amino, C1-C3 alkyl or phenyl.
[0026] In another embodiment of the present invention, R4 can be selected from the R group of α-amino acids (also known as proteinogenic amino acids, essential amino acids, or standard amino acids) such as glutamic acid, aspartic acid, lysine, arginine, histidine, alanine, valine, or tryptophan; preferably glutamic acid, aspartic acid, or lysine. For example, the R group of glutamic acid is -(CH2)2COOH, and the R group of lysine is -(CH2)4-NH2.
[0027] In another embodiment of the present invention, R5 is selected from a bond, -O-(CH2) z -NH-, -(OCH2) z -NH-, -(OCH2) z -CO-, -(OCH2CH2)z -CO- or -(OCH2CH2) z -NH-, z is selected from any integer from 1 to 3; preferably a bond, -(OCH2) z -CO-, -(OCH2CH2) z -CO- or -(OCH2CH2) z -NH-; further more preferably -(OCH2CH2) z -CO- or -(OCH2CH2) z -NH-.
[0028] In another embodiment of the present invention, according to functional classification, the toxin molecule can be a microtubule disruptor, an anti-mitotic inhibitor or a DNA damaging drug, etc.; or according to structural classification, the toxin molecule can be a toxin molecule such as maytansine, auristatin, paclitaxel, anthramycin, calicheamicin, multicarmycin, camptothecin or amanitin.
[0029] In a preferred embodiment of the present invention, the toxin molecule may be an auristatin F derivative having the following structure:
[0030] In another preferred embodiment of the present invention, the toxin molecule may be an isotecan analogue having the following structure:
[0031] For the sake of simplicity, the "compound of formula (I)" or "compound of the present application" mentioned below may also include any isotope-labeled compound of the compound of formula (I), or its optical isomers, geometric isomers, tautomers or isomer mixtures, or its pharmaceutically acceptable salts, or its prodrugs, or its metabolites.
[0032] The term "optical isomer" means that when a compound has one or more chiral centers, each chiral center can exist in the R configuration or the S configuration, and the various isomers thus formed are optical isomers. Optical isomers include all diastereomers, enantiomers, meso-isomers, racemates, or mixtures thereof. For example, optical isomers can be separated by chiral chromatography or by chiral synthesis.
[0033] The term "geometric isomer" means that when a compound has a double bond, the compound may exist as cis-isomers, trans-isomers, E-isomers and Z-isomers. Geometric isomers include cis-isomers, trans-isomers, E-isomers, Z-isomers or mixtures thereof.
[0034] The term "tautomer" refers to isomers that result from the rapid shift of an atom between two positions in a molecule. Those skilled in the art will appreciate that tautomers can transform into each other and, under certain conditions, may reach an equilibrium state and coexist.
[0035] Unless otherwise indicated, references herein to "a compound of formula (I)" or "a compound of the present invention" also encompass isotopically labeled compounds in which any atom in the compound is replaced by an isotope thereof. The present invention includes all pharmaceutically acceptable isotopically labeled compounds of the compound of formula (I) in which one or more atoms are replaced by an atom having the same atomic number as the atom commonly found in nature but a different atomic mass or mass number.
[0036] Examples of suitable isotopes for inclusion in the compounds of the present invention include isotopes of hydrogen such as 2 H (D) and 3 H(T), isotopes of carbon, such as 11 C. 13 C and 14 C, isotopes of chlorine, such as 37 Cl, isotopes of fluorine, such as 18 F, isotopes of iodine, such as 123 I and 125 I, isotopes of nitrogen, such as 13 N and 15 N, isotopes of oxygen, such as 15 O. 17 O and 18 O, and isotopes of sulfur such as 35 S.
[0037] Isotopically labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by using an appropriate isotopically labeled reagent in place of the non-labeled reagent previously used in an analogous manner to the methods described in the Examples and Preparations appended herein.
[0038] The compounds of formula (I) may exist in the form of pharmaceutically acceptable salts, for example, acid addition salts and / or base addition salts of the compounds of formula (I). Unless otherwise indicated, "pharmaceutically acceptable salts" as used herein include acid addition salts or base addition salts that may be present in the compounds of formula (I).
[0039] Pharmaceutically acceptable salts of the compounds of formula (I) include acid addition salts and base addition salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include, but are not limited to, acetate, adipate, aspartate, benzoate, benzenesulfonate, bicarbonate / carbonate, bisulfate / sulfate, borate, camphorsulfonate, citrate, cyclamates, edisylate, formate, fumarate, glucoheptonate, gluconate, glucuronate, hexafluorophosphate, 2-(4-hydroxybenzyl)benzoate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, 2-hydroxyethanesulfonate, lactate, malate, maleate, malonate, methanesulfonate, methylsulfate, naphthoate, 2-naphthalenesulfonate, nicotinate, nitrate, orotate, oxalate, hexadecanoate, phosphate / hydrogenphosphate / dihydrogenphosphate, pyroglutamate, glucarate, stearate, salicylate, tannate, tartrate, toluenesulfonate, and trifluoroacetate. Suitable base addition salts are formed with bases which form non-toxic salts. Examples include, but are not limited to, aluminum, arginine, calcium, choline, diethylamine, diethanolamine, glycine, lysine, magnesium, meglumine, ethanolamine, potassium, sodium, tromethamine, and zinc salts. Hemi-salts of acids and bases, such as hemisulfate and hemicalcium salts, can also be formed. For a review of suitable salts, see Handbook of Pharmaceutical Salts: Properties, Selection and Use by Stahl and Wermuth (Wiley-VCH, 2002). Methods for preparing pharmaceutically acceptable salts of the compounds described herein are known to those skilled in the art.
[0040] Certain compounds of the present invention may exist in unsolvated forms as well as solvated forms (including hydrated forms). In general, compounds of formula (I) are encompassed within the scope of the present invention regardless of whether they exist in solvated or unsolvated forms.
[0041] Certain compounds of the present invention may exist in different crystalline or amorphous forms. Regardless of the form in which they exist, the compounds of formula (I) are included within the scope of the present invention.
[0042] To avoid ambiguity, the following definitions are given for the terms used in this document. Unless otherwise specified, the meanings of the terms used in this document are as follows.
[0043] The term "pharmaceutically acceptable" refers to a compound, carrier or molecule that is suitable for administration to a human. Preferably, the term refers to a compound, carrier or molecule that is approved by any national regulatory agency such as CFDA (China), EMEA (Europe), FDA (USA) for use in mammals, preferably humans.
[0044] "Prodrug" refers to a derivative that is converted into the compound of the present invention by reactions with enzymes, gastric acid, etc. under physiological conditions in vivo, for example, by oxidation, reduction, hydrolysis, etc., each catalyzed by an enzyme.
[0045] "Metabolites" refer to all molecules derived from any compound of the invention in a cell or organism, preferably a human.
[0046] As used herein, the term "substituted" means that one or more (preferably 1 to 5, more preferably 1 to 3) hydrogen atoms in the group are independently replaced by a corresponding number of substituents.
[0047] As used herein, the term "independently" means that when there are more than one substituent, the substituents may be the same or different.
[0048] As used herein, the term "optional" or "optionally" means that the event it describes may or may not occur. For example, a group "optionally substituted" means that the group may be unsubstituted or substituted.
[0049] As used herein, the term "alkyl" refers to a saturated aliphatic hydrocarbon, including straight and branched chains. In some embodiments, the alkyl group has 1-8, or 1-6, or 1-3 carbon atoms. For example, the term "C 1-8 "Alkyl" refers to a straight or branched chain radical having 1 to 8 carbon atoms. 1-8 "Alkyl" includes in its definition the term "C 1-6 "C1-C3 alkyl" and "C1-C4 alkyl". Examples of alkyl include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, 3-pentyl, isopentyl, neopentyl, (R)-2-methylbutyl, (S)-2-methylbutyl, 3-methylbutyl, 2,3-dimethylpropyl, 2,3-dimethylbutyl, hexyl, and the like. The alkyl group may be optionally substituted with one or more (e.g., 1 to 5) suitable substituents.
[0050] As used herein, the term "haloalkyl" refers to an alkyl group having one or more halogen substituents (up to a perhaloalkyl group, i.e., each hydrogen atom of the alkyl group is replaced by a halogen atom). For example, the term "C1-C6 haloalkyl" refers to a C1-C6 haloalkyl group having one or more halogen substituents. 1-6 Alkyl groups (up to perhaloalkyl groups, i.e., each hydrogen atom of the alkyl group is replaced by a halogen atom). As another example, the term "C1-C4 haloalkyl" refers to a C1-C4 haloalkyl group having one or more halogen substituents. 1-4 Alkyl groups (up to perhaloalkyl, i.e., each hydrogen atom of the alkyl group is replaced by a halogen atom); the term "C 1-3"Haloalkyl" refers to a C 1-3 Alkyl groups (up to perhaloalkyl, i.e., each hydrogen atom of the alkyl group is replaced by a halogen atom); and the term "C 1-2 "Haloalkyl" refers to a C 1-2 An alkyl group (i.e., a methyl or ethyl group) (up to a perhaloalkyl group, i.e., each hydrogen atom of the alkyl group is replaced by a halogen atom). As another example, the term "C1 haloalkyl" refers to a methyl group having 1, 2, or 3 halogen substituents. Examples of haloalkyl groups include CF3, C2F5, CHF2, CH2F, CH2CF3, CH2Cl, and the like.
[0051] As used herein, the term "C3-C6 cycloalkyl group" refers to a cycloalkyl group having 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0052] As used herein, numerical ranges related to the number of substituents, carbon atoms, or ring atoms represent a complete enumeration of all integers within the range, and ranges are intended merely as a simplified notation. For example, "1-4 substituents" means 1, 2, 3, or 4 substituents; "3-8 ring atoms" means 3, 4, 5, 6, 7, or 8 ring atoms. Therefore, numerical ranges related to the number of substituents, carbon atoms, or ring atoms also encompass any subranges thereof, and each subrange is considered disclosed herein.
[0053] The compounds of the present invention can be prepared by various methods known to those skilled in the art of organic synthesis. Those skilled in the art can refer to the synthetic routes of the specific compounds of the specific examples of the present invention and make appropriate adjustments to the reaction raw materials and reaction conditions to obtain synthetic methods for other compounds.
[0054] In a second aspect, the present application provides a conjugate, which includes a compound according to the aforementioned formula (I) or an isotope-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt or solvate thereof as a conjugation precursor of the conjugate.
[0055] In one embodiment of the present invention, the conjugate includes a targeting moiety. As used herein, the term "targeting moiety" is a chemical moiety capable of binding to a biological entity, such as an antibody, a synthetic functionalized antibody, an enzyme, a protein or peptide, or any other targeting ligand. The targeting moiety can localize a therapeutic agent or small molecule to a specific target site, such as a tumor or tissue. This can effectively increase the efficacy of the therapeutic agent at the target site while minimizing unwanted side effects on normal cells.
[0056] In one embodiment of the present invention, the targeting moiety may include, but is not limited to, an antibody or synthetic functionalized antibody specific for an antigen selected from the group consisting of HER2, EGFR, Claudin18.2, c-MET, Nectin-4, ROR1, GPNMB, CD56, TACSTD2 (TROP2), CEACAM5, folate receptor-α, mesothelin, ENPP3, guanylate cyclase C, SLC44A4, NaPi2b, CD70, mucin 1, STEAP1, connexin 4, 5T4, SLTRK6, SC-16, LIV-1, P-cadherin, PSMA, fibronectin extradomain B, endothelin receptor ETB, tenascin c, collagen IV, VEGFR2, periostin, CD30, CD79b, CD19, CD22, CD138, CD37, CD33, CD74, CD19 and CD98. In a preferred embodiment of the present invention, the targeting moiety may be trastuzumab or synthetically functionalized trastuzumab.
[0057] In one embodiment of the invention, the targeting moiety can be coupled to the maleimide group of the compound of formula (I) by reducing the interchain disulfide bond to form a free sulfhydryl group (i.e., through -S-). In a preferred embodiment of the present invention, the DAR value of the antibody conjugate is any integer or decimal in 1-10, preferably 4-8 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or any decimal therebetween, preferably, the DAR value is 4-8, more particularly 6.9, 7.45, etc.). When used herein, the term "DAR value" represents the average number of toxin molecules attached to each monoclonal antibody.
[0058] In a third aspect, the present application provides a pharmaceutical composition comprising a compound of formula (I) or an isotope-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof, or the above-mentioned conjugate; and a pharmaceutically acceptable carrier.
[0059] Pharmaceutically acceptable carriers can be organic or inorganic inert carrier materials. For example, suitable carriers include water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, petrolatum, mannitol, cellulose, cellulose derivatives, saccharin sodium, glucose, sucrose, magnesium carbonate, saline, glycerol, ethanol, etc. In addition, the pharmaceutical composition may also contain other pharmaceutical additives, such as flavoring agents, preservatives, stabilizers, emulsifiers, buffers, diluents, binders, wetting agents, disintegrants, lubricants, glidants, etc.
[0060] The dosage form of the pharmaceutical composition of the present application can be a liquid dosage form, a solid dosage form or a semisolid dosage form. The liquid dosage form can be a solution (including a true solution and a colloidal solution), an emulsion (including an o / w type, a w / o type and a multiple emulsion), a suspension, an injection (including an aqueous injection, a powder injection and an infusion), an eye drop, a nasal drop, a lotion and a liniment, etc.; the solid dosage form can be a tablet (including a conventional tablet, an enteric-coated tablet, a lozenge, a dispersible tablet, a chewable tablet, an effervescent tablet, an orally disintegrating tablet), a capsule (including a hard capsule, a soft capsule, an enteric-coated capsule), a granule, a powder, a pill, a suppository, a film, a patch, an aerosol, a spray, etc.; the semisolid dosage form can be an ointment, a gel, a paste, etc. The pharmaceutical composition of the present application can be made into a conventional preparation, a sustained-release preparation, a controlled-release preparation, a targeted preparation and various microparticle delivery systems.
[0061] In some embodiments, the dosage form of the pharmaceutical composition is selected from tablets, capsules, granules, powders, syrups, inhalants and injections.
[0062] Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert excipient (or carrier) (e.g., sodium citrate or dicalcium phosphate) and may also include: (a) fillers or admixtures (e.g., starch, lactose, sucrose, glucose, mannitol, and silicic acid); (b) binders (e.g., carboxymethylcellulose, alginate, gelatin, polyvinyl pyrrolidone, sucrose, and gum arabic); (c) humectants (e.g., glycerol); (d) disintegrants (e.g., agar); (e.g., fat-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain synthetic silicates, sodium carbonate); (e) solution retarding agents (e.g., paraffin); (f) absorption promoters (e.g., quaternary ammonium compounds); (g) wetting agents (e.g., cetyl alcohol and glycerol monostearate); (h) adsorbents (e.g., kaolin and bentonite) and (i) lubricants (e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate), or mixtures thereof.
[0063] Preparations suitable for parenteral administration, such as injections, may include aqueous and non-aqueous isotonic sterile solutions suitable for injection, as well as aqueous and non-aqueous sterile suspensions. The parenteral formulations provided herein are optionally contained in unit dose or multi-dose sealed containers (e.g., ampoules) and can be stored under freeze-dried (lyophilized) conditions requiring only the addition of a sterile liquid carrier (e.g., water for injection) just before use. Examples of suitable diluents for reconstructing pharmaceutical compositions (e.g., before injection) include antibacterial water for injection, 5% glucose aqueous solution, phosphate-buffered saline, Ringer's solution, saline, sterile water, deionized water, and combinations thereof.
[0064] Sprays may contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder, or mixtures of these substances. Sprays may additionally contain conventional propellants, such as chlorofluorocarbons and volatile unsubstituted hydrocarbons, such as butane and propane. Inhalants may contain excipients such as lactose, or aqueous solutions containing, for example, polyethylene oxide-9-lauryl ether, glycocholate and deoxycholate, or oily solutions administered as nasal drops or sprays, or in the form of gels.
[0065] The content of the compound of the present application in the pharmaceutical composition can be adjusted according to actual needs (such as dosage form, administration method, administration target, etc.), for example, 0.1-95% by weight, such as 1-95% by weight, 5-90% by weight, 10-80% by weight, etc.
[0066] Specifically, the pharmaceutical composition of the present application may specifically contain 0.001-10 g (eg, 0.05 g, 0.1 g, 0.5 g, 1 g or 5 g, etc.) of the compound of the present application.
[0067] In a fourth aspect, the present application provides a compound of formula (I) or an isotope-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof, or the use of the above-mentioned conjugate in the preparation of a medicament for treating or preventing cancer in a subject in need thereof. A compound of formula (I) or an isotope-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof, or the above-mentioned conjugate can be used to treat or prevent the cancer in a subject in need thereof.
[0068] The term "subject" as used herein refers to any human or non-human organism that can potentially benefit from treatment with a compound of formula (I). Exemplary subjects include humans or mammals of any age. Preferably, the subject is a human.
[0069] As used herein, the term "treat" includes treatment of a disease or symptom in a mammal, particularly a human, and includes: (a) inhibiting the infection, disease or symptom, i.e., arresting or delaying the development of the infection, disease or symptom; (b) relieving the infection, disease or symptom, i.e., causing regression of the disease or symptom, and / or (c) curing the infection, disease or symptom.
[0070] As used herein, the term "prophylaxis" includes prophylactic therapy in mammals, particularly humans, to reduce the likelihood of developing an infection, disease, or symptom. Patients may be selected for prophylactic therapy based on their increased risk of developing an infection, disease, or symptom compared to the general population. "Prophylaxis" may include treatment of subjects who have not yet developed an infection or clinical condition, and prevention of a second occurrence of the same or similar infection or clinical condition.
[0071] In one embodiment of the present invention, the cancer can be various cancers known in the art, including but not limited to, for example, bone cancer, brain cancer, breast cancer, cervical cancer, laryngeal cancer, lung cancer, pancreatic cancer, prostate cancer, skin cancer, spinal cancer, stomach cancer, uterine cancer, and / or lymphoma. In a preferred embodiment of the present invention, the cancer can be a HER2-positive cancer. In a more preferred embodiment of the present invention, the HER2-positive cancer can be a cancer in which HER2 is overexpressed. In a further preferred embodiment of the present invention, the cancer can be breast cancer.
[0072] In a fifth aspect, the present application provides a method for treating or preventing cancer, comprising administering a therapeutically effective amount of the above-mentioned drug or pharmaceutical composition of the present invention to a subject in need thereof.
[0073] In some embodiments, the compounds of the present invention can be administered orally, parenterally, intravenously, intramuscularly, subcutaneously, nasally, orally, through the oral mucosa, ophthalmically, through the lungs, through the respiratory tract, through the vagina, through the rectum, intraperitoneally, intralesionally, or around the lesion.
[0074] "Therapeutically effective amount" refers to an amount of the compound of the present invention that is effective in treating or preventing cancer, inhibiting cancer cell proliferation, and / or reducing tumor volume when administered alone or in combination.
[0075] The specific dosage will depend on the route of administration, the severity of the disease, the age and weight of the patient, and other factors that the attending physician generally considers when determining the individual regimen and dosage level that is most suitable for a particular patient. For example, the daily dose of the compound of the present application can be particularly 0.001-150 mg / kg body weight (e.g., 0.1 mg / kg body weight, 1 mg / kg body weight, 10 mg / kg body weight or 100 mg / kg body weight, etc.).
[0076] The specific administration frequency can be determined by technicians in the relevant field, for example, once a day, once every two days, once every three days, once every four days, once every five days, once every six days, twice a day, three times a day, etc.
[0077] Those skilled in the art will appreciate that the definitions and preferences described in one aspect of the present application are equally applicable to other aspects. Those skilled in the art will appreciate that the embodiments of the various aspects of the present application can be combined in various ways without departing from the subject matter and ideas of the present application, and these combinations are also included in the scope of the present application. BRIEF DESCRIPTION OF THE DRAWINGS
[0078] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the following detailed description, they are used to explain the present invention but do not constitute a limitation of the present invention. In the accompanying drawings:
[0079] FIG1 shows a growth curve of tumor volume of mice in each group in a subcutaneous xenograft model of human breast cancer JIMT-1 according to one embodiment of the present invention, wherein the data are expressed as “mean ± standard error”; and
[0080] FIG2 shows a curve showing changes in body weight of each group over treatment time in a human breast cancer JIMT-1 subcutaneous xenograft model according to one embodiment of the present invention, wherein the data are expressed as “mean ± standard error”. DETAILED DESCRIPTION
[0081] The compounds of formula (I) of the present application can be synthesized using a variety of methods familiar to those skilled in the art of organic synthesis. The following specific examples provide some exemplary methods for synthesizing compounds of formula (I), which are well known in the field of synthetic chemistry. Obviously, by referring to the exemplary schemes in this patent, those skilled in the art can easily design synthetic routes for other compounds of formula (I) by appropriately adjusting the reactants, reaction conditions, and protecting groups.
[0082] The present invention is further illustrated below with reference to examples; however, these examples are not intended to limit the scope of the present invention. Unless otherwise stated, all reactants used in the examples were obtained from commercial sources; and the instruments and equipment used in the synthesis experiments and product analysis and testing were conventional instruments and equipment commonly used in organic synthesis.
[0083] The structures of the compounds were determined by nuclear magnetic resonance (NMR) or mass spectrometry (MS). NMR measurements were performed using a Bruker AVANCE-400 NMR spectrometer. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDC13), deuterated methanol (CD3OD), and deuterated water (D2O). The internal standard was tetramethylsilane (TMS). Chemical shifts were calculated based on a 10 -6The units are given as ppm. MS measurements were performed using a Waters ESI mass spectrometer (Acquity H-Class LC / MS). HPLC measurements were performed using an Agilent 1260 Infinity II high-pressure liquid chromatograph. Preparative HPLC was performed using a Waters Prep-HPLC system (Unitary C18 250 × 20 mm column). Normal phase preparation was performed using a Biotage Selekt chromatography purification system.
[0084] Abbreviations used herein have the definitions shown in Table 1 below.
[0085] Table 1
[0086] Example 1: Preparation of compound DL-1
[0087] Step 1: Synthesis of 2-(2-((S)-2-((2R,3R)-3-(S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-ethoxy-2-methylpropionamido)3-phenylpropionamido(ethoxy)ethyl(tert-butoxycarbonyl)-L-valine
[0088] Compound 1 (181 mg, 0.217 mmol) and Boc-valine (236 mg, 1.086 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature to dissolve. The mixture was then placed in an ice bath and DIEA (450 μL, 2.713 mmol), HOBT (205 mg, 1.519 mmol), and EDCI (262 mg, 1.367 mmol) were added sequentially at 0-5°C. The reaction was allowed to proceed at 0-5°C for 3 hours, followed by 12 hours at room temperature. The reaction was considered complete when LCMS showed less than 3% of compound 1 in the reaction solution. The reaction solution was diluted 2-fold and washed sequentially with water (15 mL) and saturated brine (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent evaporated under reduced pressure. The crude product was purified by silica gel column chromatography using 10% MeOH / DCM to obtain compound 2 (white solid, 320 mg, 143% yield). MS: 1033.38 [M+H] + .
[0089] Step 2: Synthesis of ethyl 2-(2-((S)-2-((2R,3R)-3-(S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-ethoxy-2-methylpropionamido)3-phenylpropionamido(ethoxy)L-valine
[0090] Compound 2 (320 mg, 0.31 mmol) was placed in a 25 mL single-necked flask. Dichloromethane (5 mL) and HCl / 1,4-dioxane solution (2 mL, 4 M) were added. The mixture was allowed to react at room temperature for 1 h. LCMS analysis confirmed the complete reaction of the starting compound 3. After spin drying, compound 3 was obtained (white solid, 337 mg, yield 116.6%). MS: 933.26 [M+H] + .
[0091] Step 3: Synthesis of tert-butyl (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,18-dimethyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazanonan-17-yl)amino)-5-oxopentanoate
[0092] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (46 mg, 0.107 mmol) and HATU (49 mg, 0.107 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 10 minutes. DIEA (71 μL, 0.428 mmol) was then added and stirred at room temperature for 10 minutes. Finally, compound 3 (100 mg, 0.107 mmol) was added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 3 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by silica gel column chromatography using MeOH / DCM to obtain compound 4 (white solid, 128 mg, 89% yield). MS: 670.86 [M+2H] 2+ / 2.
[0093] Step 4: Synthesis of tert-butyl (S)-4-amino-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1)-((3R,4S,5S)-4-((S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,18-dimethyl-5,8,16-trioxo-2,12,15-trioxo-6,9-diazanonadecan-17-yl)amino)-5-oxopentanoate
[0094] Compound 4 (128 mg, 0.096 mmol) was placed in a 25 mL single-necked flask, and N,N-dimethylformamide (5 mL) and piperidine (0.5 mL) were added. The mixture was allowed to react at room temperature for 10 minutes. LCMS monitored the complete reaction of compound 4. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 5 was obtained as a white solid, 24 mg, yield 22.6%. MS: 1118.48 [M+H] + .
[0095] Step 5: Synthesis of (3R,4R,7S,17S,20S)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-24-((tert-butoxycarbonyl)amino)-3-((S)-1-((3R,4S,5S))-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-17-isopropyl-4-methyl-5,8,16,19,22-pentaoxo-2,12,15-trioxo-6,9,18,21-tetraazahexacan-26-oic acid
[0096] Compound 3-Boc-aminoglutaric acid (11 mg, 0.043 mmol) and HATU (20 mg, 0.052 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 10 minutes. DIEA (28 uL, 0.172 mmol) was then added and stirred at room temperature for 10 minutes. Finally, compound 5 (24 mg, 0.021 mmol) was added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 5 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 6 (white solid, 17 mg, 58.8% yield) was obtained. MS: 674.36 [M+2H] 2+ / 2.
[0097] Step 6: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaazepan-14-yl(10S,13S)-10-(3-(tert-butoxy)-3-oxopropyl)-13-isopropyl-2,2-dimethyl-6-(2-(methyl((2S,3R,4R,5R)-2,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,8,11-trioxo-3-oxo-5,9,12-triazatetradecane-14-oate
[0098] Meglumine (17 mg, 0.013 mmol) and HATU (5.7 mg, 0.015 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. DIEA (8 uL, 0.051 mmol) was then added and stirred at room temperature for 10 minutes. Finally, compound 6 (7.4 mg, 0.038 mmol) was added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 6 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 7 (white solid, 11 mg, 57.9% yield) was obtained. MS: 763.95 [M+2H] 2+ / 2.
[0099] Step 7: Synthesis of (3R,4R,7S,17S,20S)-20-(3-amino-5-(methyl((2S,3R,7R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanamide)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-17-isopropyl-4-methyl-5,8,16,19-tetraoxo-2,12,15-trioxa-6,9,18-triazatriazole-23-octanoic acid
[0100] Compound 7 (11 mg, 0.0072 mmol) was added to dichloromethane (2 mL) and HCl / 1,4-dioxane solution (1 ml, 4 M). The mixture was allowed to react at room temperature for 1 h. LCMS confirmed the complete reaction. After spin drying, compound 8 was obtained (white solid, 17 mg, 173.5% yield). MS: 684.84 [M+2H] 2+ / 2.
[0101] Step 8: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,18-dimethyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazanonadecan-1 Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-3,3-(2-(methyl((2S,3R,5R)-2,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,35-trioxo-7,10,13,16,19,22,25,28-octaoxo-4,32,36-triazatetraenoic acid)
[0102] Maleimidooctaethylene glycol propionic acid (7.4 mg, 0.0124 mmol) and HATU (5.7 mg, 0.0149 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (6.4 uL, 0.0496 mmol) was then added and stirred at room temperature for 10 minutes. Finally, compound 8 (17 mg, 0.0124 mmol) was added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 8 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Freeze-dried to obtain compound DL-1 (white solid, 7 mg, 29.2% yield). MS: 1943.31 [M+H] +
[0103] 1 H NMR(400MHz,D2O)δ7.36–7.11(m,5H),6.79(s,2H),4.24(s,5H),4.01(s,2H),3.71(m,5H),3.67(m,4H ),3.62(m,14H),3.61(m,5H),3.60–3.55(m,7H),3.48(m,3H),3.30(s,2H),3.25(m,6H),3.14(s,1H), 3.12(s,1H),3.08(s,2H),3.05m,1H),2.85(m,2H),2.55–2.36(m,7H),2.35–2.06(m,6H),1.78(m,4H) ,1.57(s,4H),1.26(m,5H),1.12(m,1H),1.03(m,3H),0.94(m,8H),0.85(d,J=5.6Hz,8H),0.78(m,4H).
[0104] Example 2: Preparation of compound DL-2
[0105] Step 1: Synthesis of tert-butyl (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate
[0106] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (71 mg, 0.166 mmol) and HATU (75 mg, 0.197 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 10 minutes. DIEA (110 μL, 0.667 mmol) was then added and stirred at room temperature for 10 minutes. Finally, compound 9 (150 mg, 0.166 mmol) was added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 9 in the reaction solution. The reaction solution was diluted 2-fold and washed sequentially with water (15 mL) and saturated brine (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The crude product was purified by silica gel column chromatography using 3% MeOH / DCM. Compound 10 (white solid, 177 mg, 81% yield) was obtained. MS: 656.8 [M+2H] 2+ / 2
[0107] Step 2: Synthesis of tert-butyl (S)-4-amino-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate
[0108] Compound 10 (177 mg, 0.135 mmol) was placed in a 25 mL single-necked flask, and N,N-dimethylformamide (5 mL) and piperidine (0.5 mL) were added. The mixture was allowed to react at room temperature for 10 minutes. LCMS confirmed the complete reaction of compound 10. After spin drying, a white solid was obtained, which was then repeatedly washed with 50 mL of petroleum ether to remove impurities, yielding compound 11 (white solid, 150 mg, yield 102%). MS: 1090.43 [M+H]+
[0109] Step 3:
[0110] Synthesis of (3R,4R,7S,17S,20S)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-24-((tert-butoxycarbonyl)amino)-3-(S)-1-((3R,4S,5S)-4-((S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19,22-pentaoxo-2,12,15-trioxo-6,9,18,21-tetraazahexacan-26-oic acid
[0111] Compound 3-Boc-aminoglutaric acid (41 mg, 0.165 mmol) and HATU (63 mg, 0.165 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 10 minutes. DIEA (92 uL, 0.552 mmol) was then added and stirred at room temperature for 10 minutes. Finally, compound 11 (150 mg, 0.138 mmol) was added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 11 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 12 was obtained (white solid, 121 mg, 66.5% yield). MS: 660.33 [M+2H] 2+ / 2
[0112] Step 4: (3R,4R,7S)-7-Benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazo Synthesis of Heterotetradec-14-yl (10S,13S)-10-(3-(tert-butoxy)-3-oxopropyl)-2,2,13-trimethyl-6-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,811-trioxy-3-oxo-5,9,12-triazatetradec-14-yl ester
[0113] Meglumine (134 mg, 0.102 mmol) and HATU (47 mg, 0.122 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 10 minutes. DIEA (92 μL, 0.552 mmol) was then added and stirred at room temperature for 10 minutes. Finally, compound 12 (150 mg, 0.138 mmol) was added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 12 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 13 was obtained (white solid, 124 mg, 81.3% yield). MS: 748.93 [M+2H] 2+ / 2
[0114] Step 5: Synthesis of (3R,4R,7S,17S,20S)-20-(3-amino-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanamido)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19-tetraoxo-2,12,15-trioxo-6,9,18-triazatriazole-23-oic acid
[0115] Compound 13 (124 mg, 0.083 mmol) was placed in a 25 mL single-necked vial, and dichloromethane (5 mL) and HCl / ethyl acetate solution (1 mL, 4 M) were added. The reaction was allowed to proceed at room temperature for 1 h. LCMS confirmed the complete reaction of compound 13. A white solid was obtained after spin drying. The crude product was purified by preparative liquid phase separation using acetonitrile / water. Freeze-dried to afford compound 14 (white solid, 100 mg, 89.9% yield). MS: 670.82 [M+2H] 2+ / 2
[0116] Step 6: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadec-17-yl)carbamoyl 1-(2,5-dioxy-2,5-dihydro-1H-pyrrolidin-1-yl)-3,3-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,31,31,35-trioxy-7,10,13,16,19,22,25,28-octaoxy-4,32,3,6-triazatetracarboxylic acid
[0117] Maleimidooctaethylene glycol propionic acid (2.8 mg, 0.0047 mmol) and HATU (2.2 mg, 0.0057 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (3.1 μL, 0.0187 mmol) was then added and stirred at room temperature for 10 minutes. Finally, compound 14 (7 mg, 0.0052 mmol) was added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 14 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Freeze-dried to obtain compound DL-2 (white solid, 2 mg, 20.1% yield). MS: 1915.26 [M+H] +
[0118] 1H NMR(400MHz,D2O)δ7.32–7.26(m,1H),7.23(d,J=4.8Hz,4H),6.79(s,2H),4.66(m,1H),4.61(m,2H),4.27–4.14(m,4H),3.81–3.69(m, 6H),3.66(m,6H),3.62(m,16H),3.61(m,6H),3.58(m,10H),3.54(s,2H),3.48(m,3H),3.45–3.40(m,2H),3.37(m,3H),3.30(s,2H),3. 28–3.20(m,8H),3.20–3.13(m,2H),3.10(m,3H),3.05(m,2H),2.92–2.79(m,9H),2.71–2.58(m,3H),2.50(d,J=15.7Hz,2H),2.42(m,7 H),2.26(s,4H),1.80(m,4H),1.35(d,J=7.3Hz,6H),1.12(d,J=6.7Hz,2H),1.03(m,4H),0.95(m,10H),0.87(m,5H),0.82–0.72(m,4H).
[0119] Example 3: Preparation of Compound DL-3
[0120] Step 1: Synthesis of ethyl 2-(2-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamide)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamide)-3-phenylpropanamide)ethoxy)L-alaninate
[0121] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (47.2 mg, 0.111 mmol) and HATU (51 mg, 0.133 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 10 minutes. DIEA (56 μL, 0.333 mmol) and compound 9 (100 mg, 0.1111 mmol) were then added and stirred at room temperature for 1 hour. LCMS indicated that the reaction solution contained less than 3% compound 9, which was considered complete. The reaction solution was diluted 2-fold and washed sequentially with water (15 mL) and saturated brine (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent evaporated under reduced pressure. The mixture was then purified by silica gel column chromatography using 3% MeOH / DCM. Compound 10 was obtained as a white solid, 130 mg, 90% yield. MS: 628.57 [M-tBu]2+ .
[0122] Step 2: Synthesis of tert-butyl (S)-4-amino-5-((((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate
[0123] Compound 10 (130 mg, 0.099 mmol) was added to N,N-dimethylformamide (5 mL) and piperidine (0.5 mL) and allowed to react at room temperature for 10 min. LCMS monitored the complete reaction of compound 10. The reaction solution was distilled under reduced pressure to remove the solvent, and then repeatedly washed with 50 x 3 mL of petroleum ether to remove impurities, yielding compound 11 (white solid, 101 mg, yield 93.5%). MS: 1090.60 [M+H] + .
[0124] Step 3: Synthesis of (3R,4R,7S,17S,20S)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-24-((tert-butoxycarbonyl)amino)-3-((S)-1-((3R,4S,5S)-4-((S-2-((S)-2(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19,22-pentaoxo-2,12,15-trioxo-6,9,18,21-tetraazahexacan-26-oic acid
[0125] Compound 3-Boc-aminoglutaric acid (25.2 mg, 0.102 mmol) and HATU (42.6 mg, 0.112 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (46.2 μL, 0.279 mmol) and compound 11 (101 mg, 0.093 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 11, which was considered complete. The reaction solution was distilled under reduced pressure to remove the solvent and purified by preparative liquid chromatography (acetonitrile / water). Compound 12 (white solid, 102 mg, 83.3% yield) was obtained. MS: 643.70 [M+Na-tBu] 2+ .
[0126] Step 4: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaanthen-14-yl(18S,21S)-18-(3-(tert-butoxy)-3-oxopropyl)-14-(tert-butoxycarbonyl)amino)-21-methyl-12,16,19-trioxy-2,5,8-trioxa-11,17,20-triazapolyoxane-22-oate
[0127] Compound 12 (31 mg, 0.0235 mmol) and HATU (10.7 mg, 0.0282 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (12.8 μL, 0.0705 mmol) and methyl-triethylene glycol-amine (7.7 mg, 0.0470 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 12, which was considered complete. The reaction solution was distilled under reduced pressure to remove the solvent and purified by preparative liquid chromatography (acetonitrile / water). Compound 15 (white solid, 21 mg, 61.0% yield) was obtained. MS: 682.63 [M-Boc] 2+ .
[0128] Step 5: Synthesis of (3R,4R,7S,17S,20S)-20-(14-amino-12-oxo-2,5,8-trioxa-11-hexadecane-16-amino)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19-tetraoxo-2,12,15-trioxo-6,9,18-triazatriazole-23-oic acid
[0129] Compound 15 (21 mg, 0.0144 mmol) was added to dichloromethane (2 mL) and a hydrochloric acid-ethyl acetate solution (1 ml, 4 M). The reaction was allowed to proceed at room temperature for 1 h. LCMS monitored the complete reaction of the starting compound 15. The solvent was removed by distillation under reduced pressure, and the product was purified by preparative liquid chromatography (acetonitrile / water). Compound 16 (white solid, 8.0 mg, 42.6% yield) was obtained. MS: 654.58 [M+2H] 2+ / 2.
[0130] Step 6: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,1 Synthesis of 1-(5-trioxy-6,9-diazaoctadec-17-yl)carbamoyl)-1-(2,5-dioxy-2,5-dihydro-1H-pyrrolidin-1-yl)-3,31,35-trioxy-33-(12-2,5,8-trioxy-11-azatridecan-13-yl)-7,13,16,19,22,25,28-octaoxy-4,32,36-triazacyclopentane-40-carboxylic acid
[0131] Compound maleimidooctaethylene glycol propionic acid (3.6 mg, 0.0061 mmol) and HATU (2.7 mg, 0.0061 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (3.1 μL, 0.0187 mmol) and compound 16 (8.0 mg, 0.0061 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 16, which was considered complete. The reaction solution was distilled under reduced pressure to remove the solvent and purified by preparative liquid phase separation (acetonitrile / water). The preparative freeze-dried product gave compound DL-3 (white solid, 6.0 mg, 52.0% yield), MS: 1883.26 [M+H] + .
[0132] 1H NMR (400MHz, DMSO-d6) δ8.40(s,1H),8.09–7.90(m,4H),7.83(d,J=5.9Hz,1H),7.68(d,J=8.2Hz,1H),7.30–7.17(m,4H),7.14( s,1H),7.00(s,2H),4.65(m,3H),4.54(m,2H),4.29(m,3H),4.12(m,3H),3.97(s,2H),3.77(m,1H),3.58(m,7H),3.50(m,31H), 3.45–3.35(m,9H),3.27–3.10(m,13H),3.07(s,1H),3.01(m,3H),2.82–2.64(m,3H),2.46–2.41(m,2H),2.33(m,6H),2.26(m,7 H),1.99(m,4H),1.74(m,5H),1.37–1.18(m,5H),1.15(s,1H),1.03(d,J=6.6Hz,2H),1.01–0.81(m,13H),0.75(t,J=7.2Hz,6H).
[0133] Example 4: Preparation of Compound DL-4
[0134] Step 1: Synthesis of ethyl 2-(2-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamide)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamide)-3-phenylpropanamide)ethoxy)L-alaninate
[0135] Compound Fmoc-5-tert-butyl L-glutamate (98.7 mg, 0.232 mmol) and HATU (92.4 mg, 0.243 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 10 minutes. DIEA (110 μL, 0.663 mmol) and compound 9 (200 mg, 0.221 mmol) were then added and stirred at room temperature for 1 hour. LCMS indicated that the reaction solution contained less than 3% compound 9, which was considered complete. The reaction solution was diluted 2-fold and washed sequentially with water (15 mL) and saturated brine (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent evaporated under reduced pressure. The mixture was then purified by silica gel column chromatography using 3% MeOH / DCM to obtain compound 10 (white solid, 210 mg, 72.4% yield). MS: 628.56 [M-tBu] 2+ .
[0136] Step 2: Synthesis of tert-butyl (S)-4-amino-5-((((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate
[0137] Compound 10 (210 mg, 0.160 mmol) was added to N,N-dimethylformamide (5 mL) and piperidine (0.5 mL) and allowed to react at room temperature for 10 min. LCMS confirmed the complete reaction of compound 10. The reaction solution was distilled under reduced pressure to remove the solvent, and then washed repeatedly with 50 mL x 3 petroleum ether to remove impurities, yielding compound 11 (white solid, 160 mg, yield 91.8%). MS: 1090.59 [M+H] + .
[0138] Step 3: (3R,4R,7S,17S,20S,28R)-24-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-3-((S)-1-((3R,4S,5S)-4-(((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido Synthesis of ((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-2,12,15-trioxy-6,9,18,21,27-pentaazanonane-29-oic acid)-( ...7-dimethyl-5,8,16,19,22,26-hexaoxy-28-oic acid)-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-2,12,15-trioxy-6,9,18,21,27-pentaazanonane-29-oic acid)
[0139] Compound 3-Fmoc-aminoglutaric acid (108.6 mg, 0.294 mmol) and HATU (55.9 mg, 0.147 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (72.9 μL, 0.441 mmol) and compound 11 (160 mg, 0.147 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 11, which was considered complete. The reaction solution was distilled under reduced pressure to remove the solvent and purified by preparative liquid chromatography (acetonitrile / water). Compound 17 (white solid, 125 mg, 59.1% yield) was obtained. MS: 693.14 [M-tBu+2H] 2+ .
[0140] Step 4: Synthesis of (3R,4R,7S,17S,20S)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-24-((tert-butoxycarbonyl)amino)-3-((S)-1-((3R,4S,5S)-4-((S-2-((S)-2(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19,22-pentaoxo-2,12,15-trioxo-6,9,18,21-tetraazahexacan-26-oic acid
[0141] Compound 17 (60 mg, 0.042 mmol) and HATU (17.5 mg, 0.046 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (20.9 μL, 0.126 mmol) and D-glucosamine hydrochloride (15.1 mg, 0.084 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 17, which was considered complete. The reaction solution was distilled under reduced pressure to remove the solvent and purified by preparative liquid phase separation (acetonitrile / water). Compound 18 (white solid, 42 mg, yield 63.0%) was prepared. MS: 800.87 [M+2H] 2+ / 2.
[0142] Step 5: Synthesis of tert-butyl (4S)-4-(3-amino-5-oxo-5-(((3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)pentamido)-5-((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate
[0143] Compound 18 (42 mg, 0.026 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 mL) and allowed to react at room temperature for 10 min. LCMS confirmed the complete reaction of compound 18. The reaction solution was distilled under reduced pressure to remove the solvent, and then washed repeatedly with 50 x 3 mL of petroleum ether to remove impurities, yielding compound 19 (white solid, 25 mg, yield 69.0%). MS: 690.64 [M+2H] 2+ / 2.
[0144] Step 6: (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaanthen-14-yl (2S,5S)-5-(3-(tert-butoxy)-3-oxopropyl)-41-(2 Synthesis of 2-((((3R,4R,5S,6R)-2,4,5-trihydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)ethyl)-14,17,20,23,26,29,32,35-octaoxa-3,6,10,38-tetraazatetraenoic acid)-2-((((3R,4R,5S,6R)-2,4,5-trihydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)ethyl)-2-((((3R,4R,5S,6R)-2,4,5-trihydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)ethyl)-14,17,20,23,26,29,32,35-octaoxa-3,6,10,38-tetraazatetraenoic acid)
[0145] Compound maleimidooctaethylene glycol propionic acid (11 mg, 0.018 mmol) and HATU (7.3 mg, 0.019 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (8.9 μL, 0.054 mmol) and compound 19 (25 mg, 0.018 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 19, which was considered to be the end of the reaction. The reaction solution was distilled under reduced pressure to remove the solvent and purified by preparative liquid phase separation (acetonitrile / water). The prepared lyophilized product gave compound 20 (white solid, 12.0 mg, 34.0% yield), MS: 988.88 [M+Na] 2+ .
[0146] Step 7: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxo- Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-6,9-diazaoctadecane-17-yl)carbamoyl)-1-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-3,31,35-trioxy-33-(2-((((3R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-7,10,13,16,19,22,25,28octaoxa-4,32,36triazatetradecane-40-oic acid
[0147] Compound 20 (12.0 mg, 0.0061 mmol) was added to dichloromethane (2 mL) and a hydrochloric acid-ethyl acetate solution (1 ml, 4 M). The reaction was allowed to proceed at room temperature for 1 h. LCMS monitored the complete reaction of the starting compound 20. The solvent was removed by distillation under reduced pressure, and the product was purified by preparative liquid chromatography (acetonitrile / water). Compound DL-4 was obtained (white solid, 4.0 mg, 34.3% yield). MS: 1899.22 [M+H] + .
[0148] 1 H NMR(400MHz,DMSO-d6)δ8.12–7.98(m,3H),7.28–7.17(m,6H),7.14(m,2H),4.67(m,2H),4.62(d,J=8.9Hz,1H),4 .57(m,2H),4.51(m,2H),3.96(s,2H),3.58–3.44(m,5H),3.41(m,5H),3.22(m,6H),3.20–3.13(m,9H),3.07(s,3H ),3.00(m,4H),2.76(m,3H),2.63(m,2H),2.41(m,5H),2.27(m,4H),2.20(m,9H),1.74(m,6H),1.48(m,3H),1.40( d,J=10.9Hz,2H),1.35–1.28(m,3H),1.24(m,8H),1.04(d,J=6.7Hz,2H),1.00–0.80(m,27H),0.79–0.49(m,13H).
[0149] Example 5: Preparation of Compound DL-5
[0150] Step 1: Synthesis of ethyl 2-(2-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamide)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamide)-3-phenylpropanamide)ethoxy)L-alaninate
[0151] Compound Fmoc-5-tert-butyl L-glutamate (98.7 mg, 0.232 mmol) and HATU (92.4 mg, 0.243 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 10 minutes. DIEA (110 μL, 0.663 mmol) and compound 9 (200 mg, 0.221 mmol) were then added and stirred at room temperature for 1 hour. LCMS indicated that the reaction solution contained less than 3% compound 9, which was considered complete. The reaction solution was diluted 2-fold and washed sequentially with water (15 mL) and saturated brine (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent evaporated under reduced pressure. The mixture was then purified by silica gel column chromatography using 3% MeOH / DCM to obtain compound 10 (white solid, 210 mg, 72.4% yield). MS: 628.56 [M-tBu] 2+ .
[0152] Step 2: Synthesis of tert-butyl (S)-4-amino-5-((((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate
[0153] Compound 10 (210 mg, 0.160 mmol) was added to N,N-dimethylformamide (5 mL) and piperidine (0.5 mL) and allowed to react at room temperature for 10 min. LCMS confirmed the complete reaction of compound 10. The reaction solution was distilled under reduced pressure to remove the solvent, and then washed repeatedly with 50 mL x 3 petroleum ether to remove impurities, yielding compound 11 (white solid, 160 mg, yield 91.8%). MS: 1090.59 [M+H] + .
[0154] Step 3: (3R,4R,7S,17S,20S,28R)-24-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-3-((S)-1-((3R,4S,5S)-4-(((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido Synthesis of ((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-2,12,15-trioxy-6,9,18,21,27-pentaazanonane-29-oic acid)-( ...7-dimethyl-5,8,16,19,22,26-hexaoxy-28-oic acid)-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-2,12,15-trioxy-6,9,18,21,27-pentaazanonane-29-oic acid)
[0155] Compound 3-Fmoc-aminoglutaric acid (108.6 mg, 0.294 mmol) and HATU (55.9 mg, 0.147 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (72.9 μL, 0.441 mmol) and compound 10 (160 mg, 0.147 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 10, which was considered complete. The reaction solution was distilled under reduced pressure to remove the solvent and purified by preparative liquid chromatography (acetonitrile / water). Compound 17 (white solid, 125 mg, 59.1% yield) was obtained. MS: 693.14 [M-tBu+2H] 2+ .
[0156] Step 4: (3R,4R,7S)-7-Benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradec-14-yl (9S,12 Synthesis of S)-9-(3-(tert-butoxy)-3-oxypropyl)-1-(9H-fluoro-9-(12-methyl-12-methyl-3,7,10-trioxy-5-(2-oxooxyoxyoxyoxyoxyoxyoxyoxyoxyoxyoxy-oxyoxypropyl)((2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl)ethyl)-2-oxa-4,8,11-triazatridecanoate 13-oate
[0157] Compound 17 (60 mg, 0.042 mmol) and HATU (17.5 mg, 0.046 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (20.9 μL, 0.126 mmol) and 1-deoxynojirimycin (13.7 mg, 0.084 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 17, which was considered complete. The reaction solution was distilled under reduced pressure to remove the solvent and purified by preparative liquid chromatography (acetonitrile / water). Compound 21 (white solid, 35 mg, 53.0% yield) was obtained. MS: 792.50 [M+2H] 2+ / 2.
[0158] Step 5: Synthesis of tert-butyl (4S)-4-(3-amino-5-oxo-5-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl)pentamido)-5-((3R,4L,7S,17S)-7-benzyl-3-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate
[0159] Compound 21 (35 mg, 0.022 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 mL) and allowed to react at room temperature for 10 min. LCMS monitored the complete reaction of compound 21. The reaction solution was distilled under reduced pressure to remove the solvent, and then washed repeatedly with 50 x 3 mL of petroleum ether to remove impurities, yielding compound 22 (white solid, 15.0 mg, yield 50.0%). MS: 682.63 [M+2H] 2+ / 2.
[0160] Step 6: (3R,4R,7S)-7-Benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-(S)-2-[(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaazaazaalkane-14-yl (2S,5S) )-5-(3-(tert-butoxy)-3-oxypropyl)-41-(2,5-dioxy-2,5-dihydro-1H-pyrrol-1-yl)-2-methyl)-2-methyl-9-(2-oxo-2-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl)ethyl)-14,17,20,23,26,29,32,35-octaoxo-3,6,10,38-tetraazabenzene tetracarboxylate
[0161] Compound maleimidooctaethylene glycol propionic acid (6.5 mg, 0.011 mmol) and HATU (4.6 mg, 0.012 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (5.5 μL, 0.033 mmol) and compound 22 (15.0 mg, 0.011 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 22, which was considered to be the end of the reaction. The reaction solution was distilled under reduced pressure to remove the solvent and purified by preparative liquid phase separation (acetonitrile / water). The preparative freeze-dried product gave compound 23 (white solid, 10.0 mg, 47.0% yield), MS: 969.86 [M+2H]. 2+ / 2.
[0162] Step 7: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadecane Synthesis of 1-(2,5-dioxodihydro-1H-pyrrolidin-1-yl)-3,31,31,31,31,35-trioxo-33-(2-oxo-2-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl)ethyl)-7,10,13,16,19,22,25,28-octaoxo-4,32,36-triazatetracan-40-oic acid
[0163] Compound 23 (10.0 mg, 0.0052 mmol) was added to dichloromethane (2 mL) and a hydrochloric acid-ethyl acetate solution (1 ml, 4 M). The reaction was allowed to proceed at room temperature for 1 h. LCMS monitored the complete reaction of the starting compound 23. The solvent was removed by distillation under reduced pressure, and the product was purified by preparative liquid chromatography (acetonitrile / water). Compound DL-5 was obtained (white solid, 4.0 mg, 41.2% yield). MS: 1883.229 [M+H] + .
[0164] 1 H NMR(400MHz,D2O)δ8.39(s,1H),7.91(d,J=20.7Hz,1H),7.36–7.16(m,5H),6.82(s,2H ),4.63(m,4H),4.40–4.30(m,2H),4.29–4.19(m,3H),4.16(s,1H),4.05(s,2H),3.81( s,2H),3.78–3.72(m,5H),3.69(m,6H),3.64(m,14H),3.62(m,5H),3.57(m,2H),3.51( m,2H),3.45(d,J=7.1Hz,2H),3.39(s,1H),3.37(d,J=5.6Hz,1H),3.33(s,2H),3.29(s, 3H),3.27(d,J=4.9Hz,2H),3.24–3.16(m,3H),3.14(s,1H),3.11(s,2H),2.90(m,6H), 2.84–2.77(m,2H),2.68(s,3H),2.53(d,J=11.1Hz,2H),2.51–2.36(m,6H),2.28(m,4H ),2.17–1.92(m,4H),1.85(m,4H),1.73–1.47(m,4H),1.38(m,4H),1.35–1.21(m,2H), 1.15(d,J=6.7Hz,2H),1.06(m,3H),1.02–0.93(m,8H),0.90(m,4H),0.86–0.74(m,3H).
[0165] Example 6: Preparation of Compound DL-6
[0166] Step 1: Synthesis of 2-(2-((S)-2-((2R,3R)-3-(S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-ethoxy-2-methylpropionamido)3-phenylpropionamido(ethoxy)ethyl(tert-butoxycarbonyl)-L-valine
[0167] Compound 1 (181 mg, 0.217 mmol) and Boc-valine (236 mg, 1.086 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature to dissolve. The mixture was then placed in an ice bath and DIEA (450 μL, 2.713 mmol), HOBT (205 mg, 1.519 mmol), and EDCI (262 mg, 1.367 mmol) were added sequentially at 0-5°C. The reaction was allowed to proceed at 0-5°C for 3 hours, followed by 12 hours at room temperature. The reaction was considered complete when LCMS showed less than 3% of compound 1 in the reaction solution. The reaction solution was diluted 2-fold and washed sequentially with water (15 mL) and saturated brine (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent evaporated under reduced pressure. The crude product was purified by silica gel column chromatography using 10% MeOH / DCM to obtain compound 2 (white solid, 320 mg, 143% yield). MS: 1033.38 [M+H] +
[0168] Step 2: Synthesis of ethyl 2-(2-((S)-2-((2R,3R)-3-(S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-ethoxy-2-methylpropionamido)3-phenylpropionamido(ethoxy)L-valine
[0169] Compound 2 (320 mg, 0.31 mmol) was placed in a 25 mL single-necked flask. Dichloromethane (5 mL) and HCl / 1,4-dioxane solution (2 mL, 4 M) were added. The mixture was allowed to react at room temperature for 1 h. LCMS confirmed the complete reaction of compound 2. After spin drying, compound 3 was obtained (white solid, 337 mg, yield 116.6%). MS: 933.26 [M+H] +
[0170] Step 3: Synthesis of tert-butyl (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,18-dimethyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazanonan-17-yl)amino)-5-oxopentanoate
[0171] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (46 mg, 0.107 mmol) and HATU (49 mg, 0.107 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 10 minutes. DIEA (71 μL, 0.428 mmol) was then added and stirred at room temperature for 10 minutes. Finally, compound 3 (100 mg, 0.107 mmol) was added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 3 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by silica gel column chromatography using MeOH / DCM. Compound 4 was obtained (white solid, 128 mg, 89% yield). MS: 670.86 [M+2H] 2+ / 2
[0172] Step 4: Synthesis of tert-butyl (S)-4-amino-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1)-((3R,4S,5S)-4-((S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,18-dimethyl-5,8,16-trioxo-2,12,15-trioxo-6,9-diazanonadecan-17-yl)amino)-5-oxopentanoate
[0173] Compound 4 (128 mg, 0.096 mmol) was placed in a 25 mL single-necked flask, and N,N-dimethylformamide (5 mL) and piperidine (0.5 mL) were added. The mixture was allowed to react at room temperature for 10 minutes. LCMS monitored the complete reaction of compound 4. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 5 was obtained as a white solid, 24 mg, yield 22.6%. MS: 1118.48 [M+H] +
[0174] Step 5: Synthesis of (3R,4R,7S,17S,20S)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-24-((tert-butoxycarbonyl)amino)-3-((S)-1-((3R,4S,5S))-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-17-isopropyl-4-methyl-5,8,16,19,22-pentaoxo-2,12,15-trioxo-6,9,18,21-tetraazahexacan-26-oic acid
[0175] Compound 3-Boc-aminoglutaric acid (11 mg, 0.043 mmol) and HATU (20 mg, 0.052 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 10 minutes. DIEA (28 uL, 0.172 mmol) was then added and stirred at room temperature for 10 minutes. Finally, compound 5 (24 mg, 0.021 mmol) was added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 5 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 6 (white solid, 17 mg, 58.8% yield) was obtained. MS: 674.36 [M+2H] 2+ / 2
[0176] Step 6: Synthesis of (3R, 4R, 7S)-7-benzyl-3-((S)-1-((3R, 4S, 5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradec-14-yl(18S, 21S)-18-(3-(tert-butoxy)-3-oxypropyl)-14-(tert-butoxycarbonyl)amino)-21-isopropyl-12,16,19-trioxy-25,8-trioxa-11,17,20-triazadocosan-22-oic acid
[0177] Compound methyl-triethylene glycol-amine (13 mg, 0.0096 mmol) and HATU (4.4 mg, 0.0115 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. DIEA (6.4 uL, 0.0384 mmol) was then added and stirred at room temperature for 10 minutes. Finally, compound 6 (3.2 mg, 0.0193 mmol) was added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 6 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 24 (white solid, 13 mg, 90.7% yield) was obtained. MS: 746.96 [M+2H] 2+ / 2
[0178] Step 7: Synthesis of (3R,4R,7S,17S,20S)-20-(14-amino-12-oxo-2,5,8-trioxa-11-azahexadecane-16-amino)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-17-isopropyl-4-methyl-5,8,16,19-tetraoxy-2,12,15-trioxy-6,9,18-triazatrioxane-23-oic acid
[0179] Compound 24 (13 mg, 0.0072 mmol) was added to dichloromethane (2 mL) and a hydrochloric acid / 1,4-dioxane solution (0.4 mL, 4 M). The mixture was allowed to react at room temperature for 0.5 h. LCMS confirmed the complete reaction of compound 24. After spin drying, compound 25 (white solid, 15 mg, 129.3% yield) was obtained. MS: 668.84 [M+2H] 2+ / 2
[0180] Step 8: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,18-dimethyl-5,8,16-trioxo-2,12,15-trioxo-6,9-diazanonane Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-3,31,35-trioxo-33-(12-oxo-2,8,8-trioxo-11-azatridecan-13-yl)-7,13,13,16,19,22,25,28-octaoxo-4,32,36-triazatetradecane-40-carboxylic acid
[0181] Maleimidooctaethylene glycol propionic acid (6.7 mg, 0.0112 mmol) and HATU (5.1 mg, 0.0134 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (7.4 uL, 0.0448 mmol) was then added and stirred at room temperature for 10 minutes. Finally, compound 25 (15 mg, 0.0112 mmol) was added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 25 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Freeze-dried to obtain compound DL-6 (white solid, 4 mg, 18.6% yield). MS: 1911.31 [M+H] +
[0182] 1 H NMR(400MHz,D2O)δ7.23(s,5H),6.79(s,2H),4.61(m,4H),4.55–4.38(m,3H),4.23(m,4H),4.02(s,2H),3.71(m,2H),3 .67(m,3H),3.61(m,15H),3.59(m,8H),3.56–3.50(m,4H),3.48(m,2H),3.42(m,2H),3.35(m,2H),3.30(s,5H),3.26(m, 3H),3.24(s,1H),3.23(s,2H),3.16(m,2H),3.12(s,1H),3.09(s,2H),2.92–2.74(m,3H),2.60(m,4H),2.50(m,3H),2.4 2(m,7H),2.32–2.07(m,5H),1.88–1.69(m,3H),1.28(m,4H),1.02(m,3H),0.94(m,7H),0.90–0.83(m,6H),0.79(m,5H).
[0183] Example 7: Preparation of Compound DL-7
[0184] Step 1: Synthesis of (S)-N-((3R,4S,5S)-1-((S)-2-((3R,4R,7S)-7-benzyl-14-hydroxy-4-methyl-5,8-dioxy-2,12-dioxy-6,9-diazatetradec-3-yl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptane-4-yl)-2-(S)-2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamide
[0185] Compound 9 (260.0 mg, 0.288 mmol) and Na2CO3 (306.0 mg, 2.88 mmol) were added to methanol (3 mL) and stirred at room temperature for 2 hours. LCMS showed that the reaction solution contained less than 3% of compound 9, which was considered complete. The reaction solution was diluted 2-fold and washed with water (15 mL) and saturated brine (15 mL) in sequence. The organic phases were combined and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure and purified by preparative liquid separation using acetonitrile / water. Compound 1 was obtained (white solid, 202.0 mg, yield 84.3%). MS: 834.56 [M+H] + .
[0186] Step 2: Synthesis of 2-(S)-2-((2R.3R)-3-(S)-1-((3R.4S.5S)-4-(S)-2-(2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-ethoxy-2-methylpropionamido)-3-phenylpropionamidoethoxy)ethyl(((9H-fluoren-9-yl)methoxy)carbonyl)-L-leucine
[0187] Compound Fmoc-L-leucine (94.7 mg, 0.268 mmol) and HATU (101.9 mg, 0.0.268 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. DIEA (121 μL, 0.729 mmol) and compound 1 (202 mg, 0.243 mmol) were then added and stirred at room temperature for 10 hours. LCMS showed that the reaction was complete when compound 1 was less than 3% in the reaction solution. The reaction solution was diluted 2-fold and washed with water (15 mL) and saturated brine (15 mL) in sequence. The organic phases were combined after two extractions, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The mixture was purified by preparative liquid separation using acetonitrile / water. Compound 26 (white solid, 283 mg, 100% yield) was obtained. MS: 585.32 [M+2H] 2+ / 2.
[0188] Step 3: Synthesis of 2-(2-(S)-2-((2R,3R)-3-(S)-1-((3R,4S,5S)-4-(S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-ethoxy-2-methylpropionamido)-3-phenylpropionamido(ethoxy)ethyl L-leucine
[0189] Compound 26 (283 mg, 0.242 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 mL) and allowed to react at room temperature for 15 minutes. LCMS monitored the complete reaction of compound 26. The reaction solution was distilled under reduced pressure to remove the solvent, and then washed repeatedly with 50 x 3 mL of petroleum ether to remove impurities, yielding compound 27 (white solid, 281 mg, yield 123%). MS: 947.69 [M+H] + .
[0190] Step 4: Synthesis of tert-butyl (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3RS,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,19-dimethyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazabicycloalk-17-yl)amino)-5-oxopentanoate
[0191] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (139.2 mg, 0.327 mmol) and HATU (124.4 mg, 0.327 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. DIEA (148 μL, 0.891 mmol) and compound 27 (281 mg, 297 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 27, which was considered complete. The reaction solution was diluted 2-fold and washed sequentially with water (15 mL) and saturated brine (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The product was purified by preparative liquid phase separation using acetonitrile / water. Compound 28 (white solid, 247 mg, 74.6% yield) was obtained. MS: 649.73 [M-tBu] 2+ .
[0192] Step 5: Synthesis of tert-butyl (S)-4-amino-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,19-dimethyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazabicycloalk-17-yl)amino)-5-oxopentanoate
[0193] Compound 28 (247 mg, 0.182 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 mL) and allowed to react at room temperature for 15 minutes. LCMS confirmed the complete reaction of compound 28. The reaction solution was distilled under reduced pressure to remove the solvent, and then washed repeatedly with 50 x 3 mL of petroleum ether to remove impurities, yielding compound 29 (white solid, 237 mg, yield 115%). MS: 566.89 [M+2H] 2+ / 2.
[0194] Step 6: Synthesis of (3R,4R,7S,17S,20S)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-24-((tert-butoxycarbonyl)amino)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-17-isobutyl-4-methyl-5,8,16,19,22-pentaoxo-2,12,15-trioxo-6,9,18,21-tetraazahexacan-26-oic acid
[0195] Compound 3-Boc-aminoglutaric acid (26.2 mg, 0.106 mmol) and HATU (40.3 mg, 0.106 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (52.5 μL, 0.318 mmol) and compound 29 (120 mg, 0.106 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 29, which was considered complete. The reaction solution was diluted 2-fold and washed sequentially with water (15 mL) and saturated brine (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The product was purified by preparative liquid phase separation using acetonitrile / water. Compound 30 (white solid, 50 mg, 34.7% yield) was obtained. MS: 631.10 [M-Boc] 2+ .
[0196] Step 7: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaazepan-14-yl(10S,13S)-10-(3-(tert-butoxy)-3-oxopropyl)-13-isobutyl-2,2-dimethyl-6-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,8,11-trioxo-3-oxo-5,9,12-triazatetradecane-14-ol
[0197] Compound meglumine (25 mg, 0.0184 mmol) and HATU (7.7 mg, 0.0202 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (9.5 μL, 0.0552 mmol) and compound 30 (7.2 mg, 0.0368 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 30, which was considered complete. The solvent was removed by distillation under reduced pressure, and the product was purified by preparative liquid phase separation using acetonitrile / water. Compound 31 (white solid, 24 mg, 84.9% yield) was obtained. MS: 719.73 [M-Boc] 2+ .
[0198] Step 8: Synthesis of (3R,4R,7S,17S,20S)-20-(3-amino-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanamide)-7-benzyl-3-(S)-1-((3R,4S,5S)-4-((S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-17-isobutyl-4-methyl-5,8,16,19-tetraoxo-2,12,15-trioxo-6,9,18-triazatriazole-23-oic acid
[0199] Compound 31 (24 mg, 0.0156 mmol) was added to dichloromethane (1.0 mL) and a solution of hydrochloric acid in ethyl acetate (0.5 mL, 4 M). The reaction was allowed to proceed at room temperature for 15 minutes. LCMS confirmed the complete reaction of the starting compound 31. The solvent was removed by distillation under reduced pressure, and the product was purified by preparative liquid phase separation using acetonitrile / water. Compound 32 (white solid, 21.5 mg, 100% yield) was obtained. MS: 691.63 [M+2H] 2+ / 2.
[0200] Step 9: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S,(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,19-dimethyl-5,8,16-trioxy-2,12,15-trioxy- Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3,3-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,35-trioxo-7,10,13,16,19,22,25-28-octaoxo-4,32,36-triazatetrapentane-40-carboxylic acid)
[0201] Compound maleimidooctaethylene glycol propionic acid (9.3 mg, 0.0156 mmol) and HATU (6.0 mg, 0.0156 mmol) were added to N,N-dimethylformamide (1.5 mL) and stirred at room temperature for 10 minutes. DIEA (8.0 μL, 0.0486 mmol) and compound 32 (21.5 mg, 0.0156 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 32, which was considered complete. The reaction solution was distilled under reduced pressure to remove the solvent and purified by preparative liquid phase separation using acetonitrile / water. The preparative lyophilization gave compound DL-7 (white solid, 4.0 mg, yield 13.2%), MS: 1957.34 [M+H] + .
[0202] 1H NMR(400MHz,D2O)δ7.30–7.13(m,5H),6.79(s,2H),4.60(d,J=9.2Hz,1H),4.48(s,1H),4.36(s,1H),4.29–4.14(m,3H),4.08– 3.86(m,3H),3.71(m,6H),3.67(m,5H),3.61(m,21H),3.60–3.55(m,8H),3.55–3.51(m,2H),3.48(m,3H),3.45–3.32(m,4H),3. 30(s,2H),3.25(m,7H),3.20–3.13(m,2H),3.10(m,3H),3.05(m,2H),2.92–2.79(m,8H),2.61(m,3H),2.55–2.32(m,9H),2.25( s,4H),1.97(s,3H),1.80(m,3H),1.59(m,6H),1.24(m,4H),1.12(s,1H),1.03(m,3H),0.95(m,10H),0.87(m,8H),0.78(s,6H).
[0203] Example 8: Preparation of Compound DL-8
[0204] Step 1: Synthesis of (S)-N-((3R,4S,5S)-1-((S)-2-((3R,4R,7S)-7-benzyl-14-hydroxy-4-methyl-5,8-dioxy-2,12-dioxy-6,9-diazatetradec-3-yl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptane-4-yl)-2-(S)-2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamide
[0205] Compound 9 (260.0 mg, 0.288 mmol) and Na2CO3 (306.0 mg, 2.88 mmol) were added to methanol (3 mL) and stirred at room temperature for 2 hours. LCMS showed that the reaction solution contained less than 3% of compound 9, which was considered complete. The reaction solution was diluted 2-fold and washed with water (15 mL) and saturated brine (15 mL) in sequence. The organic phases were combined and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure and purified by preparative liquid separation using acetonitrile / water. Compound 1 was obtained (white solid, 202.0 mg, yield 84.3%). MS: 834.56 [M+H] + .
[0206] Step 2: Synthesis of 2-(S)-2-((2R.3R)-3-(S)-1-((3R.4S.5S)-4-(S)-2-(2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-ethoxy-2-methylpropionamido)-3-phenylpropionamidoethoxy)ethyl(((9H-fluoren-9-yl)methoxy)carbonyl)-L-leucine
[0207] Compound Fmoc-L-leucine (94.7 mg, 0.268 mmol) and HATU (101.9 mg, 0.0.268 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. DIEA (121 μL, 0.729 mmol) and compound 1 (202 mg, 0.243 mmol) were then added and stirred at room temperature for 10 hours. LCMS showed that the reaction was complete when compound 1 was less than 3% in the reaction solution. The reaction solution was diluted 2-fold and washed with water (15 mL) and saturated brine (15 mL) in sequence. The organic phases were combined after two extractions, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The mixture was purified by preparative liquid separation using acetonitrile / water. Compound 26 (white solid, 283 mg, 100% yield) was obtained. MS: 586.32 [M+H] + .
[0208] Step 3: Synthesis of 2-(2-(S)-2-((2R,3R)-3-(S)-1-((3R,4S,5S)-4-(S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-ethoxy-2-methylpropionamido)-3-phenylpropionamido(ethoxy)ethyl L-leucine
[0209] Compound 26 (283 mg, 0.242 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 mL) and allowed to react at room temperature for 15 minutes. LCMS monitored the complete reaction of compound 26. The reaction solution was distilled under reduced pressure to remove the solvent, and then washed repeatedly with 50 x 3 mL of petroleum ether to remove impurities, yielding compound 27 (white solid, 281 mg, yield 123%). MS: 947.69 [M+H] + .
[0210] Step 4: Synthesis of tert-butyl (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3RS,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,19-dimethyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazabicycloalk-17-yl)amino)-5-oxopentanoate
[0211] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (139.2 mg, 0.327 mmol) and HATU (124.4 mg, 0.327 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. DIEA (148 μL, 0.891 mmol) and compound 27 (281 mg, 297 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 27, which was considered complete. The reaction solution was diluted 2-fold and washed sequentially with water (15 mL) and saturated brine (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The product was purified by preparative liquid phase separation using acetonitrile / water. Compound 28 (white solid, 247 mg, 74.6% yield) was obtained. MS: 649.73 [M-tBu] 2+ / 2.
[0212] Step 5: Synthesis of tert-butyl (S)-4-amino-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,19-dimethyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazabicycloalk-17-yl)amino)-5-oxopentanoate
[0213] Compound 28 (247 mg, 0.182 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 mL) and allowed to react at room temperature for 15 minutes. LCMS monitored the complete reaction of compound 28. The reaction solution was distilled under reduced pressure to remove the solvent, and then washed repeatedly with 50 x 3 mL of petroleum ether to remove impurities, yielding compound 29 (white solid, 237 mg, yield 115%). MS: 1132.79 [M+H] + .
[0214] Step 6: Synthesis of (3R,4R,7S,17S,20S)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-24-((tert-butoxycarbonyl)amino)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-17-isobutyl-4-methyl-5,8,16,19,22-pentaoxo-2,12,15-trioxo-6,9,18,21-tetraazahexacan-26-oic acid
[0215] Compound 3-Boc-aminoglutaric acid (26.2 mg, 0.106 mmol) and HATU (40.3 mg, 0.106 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (52.5 μL, 0.318 mmol) and compound 29 (120 mg, 0.106 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 29, which was considered complete. The reaction solution was diluted 2-fold and washed sequentially with water (15 mL) and saturated brine (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The product was purified by preparative liquid phase separation using acetonitrile / water. Compound 30 (white solid, 50 mg, 34.7% yield) was obtained. MS: 631.10 [M-Boc] 2+ / 2.
[0216] Step 7: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradec-14-yl(18S,21S)-18-(3-(tert-butoxy)-3-oxypropyl)-14-(tert-butoxycarbonyl)amino)-21-isobutyl-12,16,19-trioxy-2,58-trioxo-11,17,20-triazadocosa-22-oic acid
[0217] Compound methyl-triethylene glycol-amine (25 mg, 0.0184 mmol) and HATU (7.7 mg, 0.0202 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (9.5 μL, 0.0552 mmol) and compound 30 (6.0 mg, 0.0368 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 30, which was considered complete. The solvent was removed by distillation under reduced pressure, and the product was purified by preparative liquid phase separation using acetonitrile / water. Compound 33 (white solid, 17 mg, 61.4% yield) was obtained. MS: 703.82 [M-Boc] 2+ / 2.
[0218] Step 8: Synthesis of (3R,4R,7S,17S,20S)-20-(14-amino-12-oxo-2,5,8-trioxa-11-azahexadecane-16-amino)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-17-isobutyl-4-methyl-5,8,16,19-tetraoxy-2,12,15-trioxy-6,9,18-triazatrioxane-23-oic acid
[0219] Compound 33 (17 mg, 0.0113 mmol) was added to dichloromethane (1.0 mL) and a solution of hydrochloric acid in ethyl acetate (0.5 mL, 4 M). The reaction was allowed to proceed at room temperature for 15 minutes. LCMS confirmed the complete reaction of the starting compound 33. The solvent was removed by distillation under reduced pressure, and the product was purified by preparative liquid phase separation using acetonitrile / water. Compound 34 (white solid, 15.3 mg, 100% yield) was obtained. MS: 675.79 [M+2H] 2+ / 2.
[0220] Step 9: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,19-dimethyl-5,8,16-trioxo-2,12,15-trioxo-6,9-diazatriazole Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-3,31,35-trioxo-33-(12-oxo-2,8,8-trioxo-11-azatridecan-13-yl)-7,13,13,16,19,22,25,28-octaoxo-4,36-triazatetradecane-40-oic acid
[0221] Compound maleimidooctaethylene glycol propionic acid (6.7 mg, 0.0113 mmol) and HATU (6.0 mg, 0.0113 mmol) were added to N,N-dimethylformamide (1.5 mL) and stirred at room temperature for 10 minutes. DIEA (6.0 μL, 0.0339 mmol) and compound 34 (15.3 mg, 0.0113 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 34, which was considered complete. The reaction solution was distilled under reduced pressure to remove the solvent and purified by preparative liquid phase separation using acetonitrile / water. The preparative lyophilization yielded compound DL-8 (white solid, 3.5 mg, 16.1% yield). MS: 1925.33 [M+H] + .
[0222] 1 H NMR(400MHz,D2O)δ8.35(s,2H),7.22(s,1H),7.22(s,5H),6.79(s,2H),4.61(s,1H),4.49(m,1H),4.43–4.33(m,1H), 4.22(m,3H),4.02(s,1H),3.71(m,4H),3.66(m,3H),3.65–3.56(m,31H),3.56–3.51(m,5H),3.48(m,3H),3.30(m,8H) ,3.28–3.20(m,8H),3.20–2.99(m,7H),2.87(m,7H),2.64(m,2H),2.41(m,9H),2.32–2.15(m,1H),2.10–1.88(m,1H), 1.85–1.70(m,1H),1.61(m,5H),1.27(s,3H),1.11(s,1H),1.03(m,3H),0.95(m,10H),0.87(m,7H),0.82–0.72(m,6H).
[0223] Example 9: Preparation of Compound DL-9
[0224] Step 1: Synthesis of tert-butyl (S)-13-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-12-oxo-2,5,8-trioxa-11-azahexadecane-16-oic acid
[0225] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (130.2 mg, 0.306 mmol) and HATU (116.5 mg, 0.306 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. DIEA (152 μL, 0.306 mmol) and compound methyl-triethylene glycol-amine (50.0 mg, 0.306 mmol) were then added and stirred at room temperature for 10 hours. LCMS monitoring of the reaction was completed. The reaction solution was diluted 2-fold and washed with water (15 mL) and saturated brine (15 mL) in sequence. The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The product was purified by preparative liquid phase separation using acetonitrile / water. Compound 35 (white solid, 168.1 mg, 96.2% yield) was obtained. MS: 572.59 [M+H] + .
[0226] Step 2: Synthesis of (S)-13-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-12-oxo-2,5,8-trioxa-11-azahexadecane-16-oic acid
[0227] Compound 35 (168.1 mg, 0.295 mmol) was added to dichloromethane (1.0 mL) and trifluoroacetic acid (0.5 mL). The reaction was allowed to proceed at room temperature for 15 minutes. LCMS monitored the complete reaction of the starting compound 35. The solvent was removed by distillation under reduced pressure, and the product was purified by preparative liquid phase separation using acetonitrile / water. Compound 36 (white solid, 170.3 mg, 112.4% yield) was obtained. MS: 516.63 [M+H] + .
[0228] Step 3: Synthesis of (13S)-13-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-18-(3-(tert-butoxy)-3-oxopropyl)-12,16-dioxo-2,5,8-trioxa-11,17-diazanonan-19-oic acid
[0229] Compound L-glutamic acid-5-tert-butyl ester (170.3 mg, 0.331 mmol) and HATU (125.8 mg, 0.331 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. DIEA (164 μL, 0.993 mmol) and compound 36 (67.3 mg, 0.331 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% compound 36, which was considered complete. The reaction solution was diluted 2-fold and washed sequentially with water (15 mL) and saturated brine (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The product was purified by preparative liquid phase separation using acetonitrile / water. Compound 37 (white solid, 142.7 mg, 61.6% yield) was obtained. MS: 692.79 [M+H] + .
[0230] Step 4: Synthesis of (13S)-13-amino-18-(3-(tert-butoxy)-3-oxopropyl)-12,16-dioxo-2,5,8-trioxa-11,17-diazahexadecane-19-oic acid
[0231] Compound 37 (142.7 mg, 0.204 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 mL) and allowed to react at room temperature for 15 minutes. LCMS confirmed the complete reaction of compound 37. The reaction solution was distilled under reduced pressure to remove the solvent, and then washed repeatedly with 50 mL of petroleum ether to remove impurities, yielding compound 38 (white solid, 65.5 mg, yield 67.3%). MS: 479.42 [M+H] + .
[0232] Step 5: Synthesis of (7S)-2-(3-(tert-butoxy)-3-oxopropyl)-39-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-7-((2-(2-methoxyethoxy)ethoxyethyl)carbamoyl)-4,9,37-trioxy-12,15,18,21,24,27,30,33-octaoxy-3,8,36-triazacyclotricarboxylic acid
[0233] Maleimidooctaethylene glycol propionic acid (81.3 mg, 0.137 mmol) and HATU (52.2 mg, 0.137 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (68 μL, 0.412 mmol) and compound 38 (65.5 g, 0.137 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 38, which was considered complete. The reaction solution was diluted 2-fold and washed sequentially with water (15 mL) and saturated brine (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The product was purified by preparative liquid phase separation using acetonitrile / water. Compound 39 was obtained as a white solid (32.8 mg, 22.7% yield). MS: 1054.20 [M+H] + .
[0234] Step 6: (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaazepan-14-yl (2S,10S)-5-(3-(tert-butoxy)-3- Synthesis of 2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-10-((2-(2-(2-methoxyethoxy)ethoxyethyl)carbamoyl)-2-methyl-4,7,12,40-tetraoxo-15,18,21,24,27,30,33,36-octaoxy-3,6,11,39-tetraazatetracarboxylic acid)-4-(2-(2,5-dioxopropyl)-10-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-10-((2-(2-(2-methoxyethoxy)ethoxyethyl)carbamoyl)-2-methyl-4,7,12,40-tetraoxo-15,18,21,24,27,30,33,36-octaoxy-3,6,11,39-tetraazatetracarboxylic acid)
[0235] Compound 39 (16.4 mg, 0.0156 mmol) and HATU (5.9 mg, 0.0156 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (8 μL, 0.0468 mmol) and compound 9 (14.1 mg, 0.0368 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 39, which was considered complete. The solvent was removed by distillation under reduced pressure, and the product was purified by preparative liquid phase separation using acetonitrile / water. Compound 40 (white solid, 14.3 mg, 47.3% yield) was obtained. MS: 970.52 [M+2H] 2+ / 2.
[0236] Step 7: (33S)-38-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadecadecyl) Synthesis of 1-(2,5-dioxy-2,5-dihydro-1H-pyrrolidin-1-yl)-3,3-((2-(2-(-2-methoxyethoxy)ethoxyethyl)carbamoyl)-3,31,36-trioxo-7,10,13,16,19,22,25-28-octaoxy-4,32,37-triazabenzenetracarboxylic acid)
[0237] Compound 40 (14.3 mg, 0.0074 mmol) was added to dichloromethane (1.0 mL) and trifluoroacetic acid (0.5 mL). The reaction was allowed to proceed at room temperature for 15 minutes. LCMS monitored the complete reaction of the starting compound 40. The solvent was removed by distillation under reduced pressure, and the product was purified by preparative liquid phase separation using acetonitrile / water. Compound DL-9 was obtained (white solid, 7.6 mg, 154.7% yield). MS: 1883.26 [M+H] + .
[0238] 1 H NMR(400MHz,D2O)δ7.33–7.26(m,1H),7.26–7.19(m,5H),7.19–7.12(m,1H),6.79(s,2H),4.68(s,2H),4.66(s,1H),4.65– 4.55(m,3H),4.34(m,2H),4.28(m,2H),4.22(m,3H),4.18(m,2H),3.81–3.65(m,12H),3.60(m,49H),3.57–3.51(m,10H),3. 49(m,4H),3.37–3.32(m,5H),3.30(m,9H),3.28–3.21(m,10H),3.20–3.05(m,8H),2.96–2.75(m,11H),2.59–2.47(m,5H),2 .47–2.34(m,9H),2.34–2.15(m,6H),1.57(m,4H),1.35(m,8H),1.03(m,5H),0.99–0.90(m,14H),0.88(m,6H),0.78(m,5H).
[0239] Example 10: Preparation of Compound DL-10
[0240] Step 1: Synthesis of ethyl 2-(2-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamide)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamide)-3-phenylpropanamide)ethoxy)L-alaninate
[0241] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (50.0 mg, 0.0553 mmol) and HATU (21.0 mg, 0.0553 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (27 μL, 0.1659 mmol) and compound 9 (23.5 mg, 0.0053 mmol) were then added and stirred at room temperature for 1 hour. The reaction was considered complete when LCMS showed less than 3% of compound 9 in the reaction solution. The reaction solution was diluted 2-fold and washed sequentially with water (15 mL) and saturated brine (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The product was purified by preparative liquid phase separation using acetonitrile / water. Compound 10 (white solid, 75.2 mg, 103.7% yield) was obtained. MS: 628.65 [M-tBu] 2+ .
[0242] Step 2: Synthesis of tert-butyl (S)-4-amino-5-((((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate
[0243] Compound 10 (75.2 mg, 0.0573 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 mL) and allowed to react at room temperature for 15 minutes. LCMS confirmed the complete reaction of compound 3. The reaction solution was distilled under reduced pressure to remove the solvent, and then washed repeatedly with 50 x 3 mL of petroleum ether to remove impurities, yielding compound 11 (white solid, 60.1 mg, yield 96.2%). MS: 545.30 [M+2H] 2+ / 2.
[0244] Step 3: (3R,4R,7S,17S,20S,28R)-24-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-3-((S)-1-((3R,4S,5S)-4-(((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido Synthesis of ((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-2,12,15-trioxy-6,9,18,21,27-pentaazanonane-29-oic acid)-( ...7-dimethyl-5,8,16,19,22,26-hexaoxy-28-oic acid)-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-2,12,15-trioxy-6,9,18,21,27-pentaazanonane-29-oic acid)
[0245] Compound 3-Fmoc-aminoglutaric acid (20.3 mg, 0.0551 mmol) and HATU (380.23 mg, 0.0551 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (27 μL, 0.1652 mmol) and compound 11 (60.1 mg, 0.0551 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 11, which was considered complete. The reaction solution was diluted 2-fold and washed sequentially with water (15 mL) and saturated brine (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The product was purified by preparative liquid phase separation using acetonitrile / water. Compound 17 (white solid, 38.6 mg, 48.6% yield) was obtained. MS: 731.69 [M+Na] 2+ .
[0246] Step 4: Synthesis of (3R,4R,7S,17S,20S)-24-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-3-((S)-1-((3R,4S,5S)-4-(S)-2-(((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19,22-pentaoxy-2,12,15-trioxy-6,9,18,21-tetraazahexadecane-26-octanoic acid
[0247] Compound 17 (5.2 mg, 0.0268 mmol) and HATU (10.2 mg, 0.0268 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (13 μL, 0.0804 mmol) and D-glucosamine (38.6 mg, 0.0268 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 17, which was considered complete. The reaction solution was diluted 2-fold and washed with water (15 mL) and saturated brine (15 mL) in sequence. The organic phases were combined and extracted twice, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The product was purified by preparative liquid separation using acetonitrile / water. Compound 41 (white solid, 12.0 mg, yield 27.7%) was obtained. MS: 810.12 [M+2H] 2+ / 2.
[0248] Step 5: Synthesis of (3R,4R,7S,17S,20S,28R)-24-amino-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-3-((S)-1-((3R,4S,5S)-4-((S,2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19,22,26-hexaoxy-28-((1R,2S,3R)-1,2,4-tetrahydroxybutyl)-2,2,12,15-trioxa-6,9,18,21,27-pentaazanonane-29-oic acid
[0249] Compound 41 (12.0 mg, 0.0074 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 mL) and allowed to react at room temperature for 15 minutes. LCMS monitored the complete reaction of compound 41. The reaction solution was distilled under reduced pressure to remove the solvent, and then washed repeatedly with 50 x 3 mL of petroleum ether to remove impurities, yielding compound 42 (white solid, 10.1 mg, yield 97.6%). MS: 698.56 [M+2H] 2+ / 2.
[0250] Step 6: (2R)-6-((3R,4R,7S,17S,20S)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-3-((S)-1-((3R,4S,5S)-4-((S,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19,22-pentaoxo-2,12, Synthesis of 15-trioxo-6,9,18,21-tetraazatriazol-23-yl)-38-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-4,836-trioxy-2-(((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-11,14,17,20,23,26,26,29,32-octaoxo-3,7,35-triazaoctacarbonic acid
[0251] The compound maleimidooctaethylene glycol propionic acid (4.3 mg, 0.0072 mmol) and HATU (2.8 mg, 0.0072 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (4 μL, 0.0217 mmol) and compound 42 (10.1 mg, 0.0072 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 42, which was considered complete. The reaction solution was diluted 2-fold and washed with water (15 mL) and saturated brine (15 mL) in sequence. The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The product was purified by preparative liquid phase separation using acetonitrile / water. Compound 43 (white solid, 10.2 mg, 71.5% yield) was obtained. MS: 985.76 [M+2H] 2+ / 2.
[0252] Step 8: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S-2-((S,(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9- Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3,31,35-trioxo-7,10,13,16,19,22,25,28-octaoxo-4,32,36-triazatetradecane-40-oic acid
[0253] Compound 43 (10.2 mg, 0.0052 mmol) was added to dichloromethane (1.0 mL) and trifluoroacetic acid (0.5 mL). The reaction was allowed to proceed at room temperature for 30 minutes. LCMS monitored the complete reaction of the starting compound 43. The solvent was removed by distillation under reduced pressure, and the product was purified by preparative liquid phase separation using acetonitrile / water. Compound DL-10 (white solid, 4.5 mg, 45.4% yield) was obtained. MS: 1915.23 [M+H] + .
[0254] 1 H NMR(400MHz,D2O)δ7.22(s,5H),6.79(d,J=1.0Hz,2H),4.61(m,3H),4.33(s,1H),4.22( m,3H),4.06(s,1H),3.78–3.64(m,9H),3.62(m,21H),3.46–3.34(m,4H),3.30(s,2H),3. 28–3.20(m,6H),3.20–3.04(m,5H),2.87(m,6H),2.58–2.30(m,11H),1.76(d,J=6.9Hz,3 H),1.35(m,4H),1.27(s,3H),1.06–0.99(m,3H),0.95(m,8H),0.87(m,4H),0.77(s,3H).
[0255] Example 11: Preparation of Compound DL-11
[0256] Step 1: Synthesis of tert-butyl(3R,4R,7S,17S,20S)-20-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19-tetraoxo-2,12-dioxy-6,9,15,18-tetraazatriazole-23-ol
[0257] Compound 44 (11 mg, 0.0122 mmol), compound Fmoc-L-glutamic acid-5-tert-butyl ester (5.2 mg, 0.0122 mmol), and HATU (5.6 mg, 0.0146 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (8 uL, 0.0488 mmol) was then added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed that the reaction solution contained less than 3% of compound 1. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 45 (white solid, 13 mg, 81% yield) was obtained. MS: 656.34 [M+2H] 2+ / 2
[0258] Step 2: Synthesis of tert-butyl (3R,4R,7S,17S,20S)-20-amino-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S,(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19-tetraoxo-2,12-dioxo-6,9,15,18-tetraazatriazol-23-oic acid
[0259] Compound 45 (13 mg, 0.010 mmol) was placed in a 25 mL single-necked flask, and N,N-dimethylformamide (5 mL) and piperidine (0.5 mL) were added. The mixture was allowed to react at room temperature for 10 min. LCMS monitored the complete reaction of compound 45. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 46 (white solid, 9 mg, 83% yield) was obtained. MS: 1089.44 [M+H] +
[0260] Step 3: Synthesis of 3-((tert-Butoxycarbonyl)amino)-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoic acid
[0261] Compound 3-Boc-aminoglutaric acid (253 mg, 1.025 mmol), compound meglumine (100 mg, 0.512 mmol), and HATU (390 mg, 1.025 mmol) were added to N,N-dimethylformamide (10 mL) and stirred at room temperature for 10 minutes. DIEA (338 uL, 2.048 mmol) was then added and stirred at room temperature for 3 hours. The reaction was monitored by LCMS. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 47 (colorless oil, 627 mg, 288% yield) was obtained. MS: 425.45 [M+H] +
[0262] Step 4: Synthesis of tert-butyl(3R,4R,7S,17S,20S)-7-benzyl-20-(3-((tert-butoxycarbonyl)amino)-5-(methyl((2S,3R,4L,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanamide)-3-((S)-1-((3R,4S,5S)-4-((S(S)-2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19-tetraoxo-2,12-dioxo-6,9,15,18-tetraazatriazole-23-oic acid salt
[0263] Compound 46 (9 mg, 0.008 mmol), compound 47 (4 mg, 0.008 mmol), and HATU (4.2 mg, 0.011 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. DIEA (6 uL, 0.0368 mmol) was then added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 46 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 48 (white solid, 13 mg, 94% yield) was obtained. MS: 748.44 [M+2H] 2+ / 2
[0264] Step 5: Synthesis of (3R,4R,7S,17S,20S)-20-(3-amino-5-(methyl((2S,3R,7R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanamido)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19-tetraoxo-2,12-dioxy-6,9,15,18-tetraazatriazole-23-octanoic acid
[0265] Compound 48 (13 mg, 0.009 mmol) was placed in a 10 mL single-necked vial. Dichloromethane (2 mL) and HCl / 1,4-dioxane solution (1 mL, 4 M) were added and allowed to react at room temperature for 1 h. LCMS confirmed the complete reaction of compound 48. After spin drying, the crude product, compound 49 (white solid, 15 mg, 129% yield) was obtained. MS: 670.32 [M+2H] 2+ / 2
[0266] Step 6: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12-dioxy-6,9,15-triazaoctadec-17-yl)carbamoyl Synthesis of 1-(2,5-dioxy-2,5-dihydro-1H-pyrrol-1-yl)-3,3-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,31,31,35-trioxy-7,10,13,16,19,22,25,28-octaoxy-4,32,3,6-triazatetracarboxylic acid
[0267] Compound 49 (15 mg, 0.011 mmol), maleimidooctaethylene glycol propionic acid (5.2 mg, 0.009 mmol), and HATU (4 mg, 0.01 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. DIEA (6 uL, 0.035 mmol) was then added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 49 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound DL-11 was obtained (white solid, 3 mg, 14% yield). MS: 1914.27 [M+H] +
[0268] 1 H NMR(400MHz,D2O)δ7.37–7.13(m,5H),6.78(m,2H),4.65–4.46(m,1H),4.30–4.12(m,1H),4.04–3.90(m,1H) ,3.72(m,6H),3.60(m,50H),3.53–3.40(m,10H),3.37–3.28(m,6H),3.28–3.21(m,8H),3.20–2.98(m,8H),2 .91–2.76(m,10H),2.62(m,2H),2.43(m,10H),2.30–2.11(m,2H),2.01(m,1H),1.74(m,1H),1.66–1.42(m,1 H),1.30(m,3H),1.22(m,3H),1.11(m,1H),1.07–0.98(m,2H),0.98–0.90(m,10H),0.86(m,6H),0.78(m,5H).
[0269] Example 12: Preparation of Compound DL-12
[0270] Step 1: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradec-14-yl(S)-2-((tert-butoxycarbonyl)amino)-2-cyclopropyl acetate
[0271] Compound 1 (30 mg, 0.036 mmol), compound Boc-L-cyclopropylglycine (8 mg, 0.036 mmol), and HATU (17 mg, 0.043 mmol) were added to N,N-dimethylformamide (4 mL) and stirred at room temperature for 10 minutes. DIEA (24 uL, 0.144 mmol) was then added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed that the reaction solution contained less than 3% of compound 1. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 50 (white solid, 36 mg, 97% yield) was obtained. MS: 1031.36 [M+H] +
[0272] Step 2: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazacan-14-yl(S)-2-amino-2-cyclopropyl acetate
[0273] Compound 50 (36 mg, 0.035 mmol) was placed in a 25 mL single-necked vial. Dichloromethane (2 mL) and HCl / 1,4-dioxane solution (1 mL, 4 M) were added and allowed to react at room temperature for 1 h. LCMS monitoring confirmed the complete reaction of the starting compound 3. After spin drying, the crude product, compound 51 (white solid, 81 mg, 248% yield) was obtained. MS: 931.24 [M+H] +
[0274] Step 3: Synthesis of tert-butyl (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((3R,4R,7S,17S)-7-benzyl-17-cyclopropyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-(((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaheptan-17-yl)amino)-5-oxopentanoate
[0275] Compound 51 (81 mg, 0.087 mmol), Fmoc-L-glutamic acid-5-tert-butyl ester (37 mg, 0.087 mmol), and HATU (40 mg, 0.104 mmol) were added to N,N-dimethylformamide (4 mL) and stirred at room temperature for 10 minutes. DIEA (56 uL, 0.348 mmol) was then added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 51 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 52 (white solid, 27 mg, 23% yield) was obtained. MS: 669.86 [M+2H] 2+ / 2
[0276] Step 4: Synthesis of tert-butyl (S)-4-amino-5-(((3R,4R,7S,17S)-7-benzyl-17-cyclopropyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaheptadecan-17-yl)amino)-5-oxopentanoate
[0277] Compound 52 (27 mg, 0.02 mmol) was placed in a 25 mL single-necked flask, and N,N-dimethylformamide (5 mL) and piperidine (0.5 mL) were added. The mixture was allowed to react at room temperature for 10 min. LCMS monitored the complete reaction of compound 52. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 53 was obtained as a white solid, 24 mg, yield 106%. MS: 558.74 [M+2H] 2+ / 2
[0278] Step 5: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaazepan-14-yl(10S,13S)-10-(3-(tert-butoxy)-3-oxopropyl)-13-cyclopropyl-2,2-dimethyl-6-(2-(methyl((2S,3R,4R,5R)-2,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,8,11-trioxa-5,12-triazaazepane
[0279] Compound 47 (9 mg, 0.0.022 mmol) and HATU (10 mg, 0.026 mmol) were added to N,N-dimethylformamide (4 mL) and stirred at room temperature for 10 minutes. DIEA (11 uL, 0.086 mmol) and compound 53 (24 mg, 0.022 mmol) were then added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 53 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 54 (white solid, 22 mg, 66% yield) was obtained. MS: 761.95 [M+2H] 2+ / 2
[0280] Step 6: Synthesis of (3R,4R,7S,17S,20S)-20-(3-amino-5-(methyl((2S,3R,7R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanamide)-7-benzyl-17-cyclopropyl-3-((S)-1-((3R,4S,5S)-4-((S,2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16,19-tetraoxo-2,12,15-trioxa-6,9,18-triazatriazole-23-oic acid
[0281] Compound 54 (22 mg, 0.014 mmol) was placed in a 10 mL single-necked vial. Dichloromethane (2 mL) and trifluoroacetic acid (1 mL) were added and allowed to react at room temperature for 1 h. LCMS monitoring confirmed the complete reaction of the starting compound 54. After spin drying, the crude product, compound 55 (white solid, 36 mg, 182% yield) was obtained. MS: 683.84 [M+2H] 2+ / 2
[0282] Step 7: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-17-cyclopropyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaheptadecanoyl- Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3,3-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,35-trioxo-7,10,13,16,19,22,25-28-octaoxo-4,32,36-triazatetraenoic acid)
[0283] Maleimidooctaethylene glycol propionic acid (15 mg, 0.026 mmol) and HATU (12 mg, 0.031 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. DIEA (17 uL, 0.104 mmol) and compound 55 (36 mg, 0.026 mmol) were then added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 55 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Freeze-dried to obtain compound DL-12 (white solid, 2 mg, 4% yield). MS: 1941.3 [M+H]+
[0284] 1 H NMR (400MHz, DMSO-d6) δ8.01(s,1H),7.86(m,1H),7.68(m,1H),7.45–7.33(m,2H),7.33–7.10(m,5H),7.00(s,2H),4.67(s,3H),4.52( m,2H),4.34(m,3H),4.18(m,1H),4.12(m,2H),3.97(m,2H),3.77(m,3H),3.65–3.54(m,10H),3.49(m,32H),3.44–3.36(m,10H),3.24– 3.18(m,5H),3.15(m,3H),3.07(m,1H),3.00(m,4H),2.80(m,1H),2.76–2.66(m,2H),2.58–2.52(m,3H),2.33(m,3H),2.24(m,7H),1.7 4(m,3H),1.62(m,2H),1.43(m,3H),1.21(m,3H),1.06(m,3H),1.00–0.81(m,15H),0.75(m,5H),0.51(s,2H),0.38(s,1H),0.30(s,1H).
[0285] Example 13: Preparation of Compound DL-13
[0286] Step 1: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaazapyridin-14-yl 1-(((benzyloxy)carbonyl)amino)cyclopropane-1-carboxylate
[0287] Compound 1 (30 mg, 0.036 mmol), compound 1-Cbz-aminocyclopropanecarboxylic acid (8.5 mg, 0.036 mmol), and HATU (16 mg, 0.043 mmol) were added to N,N-dimethylformamide (4 mL) and stirred at room temperature for 10 minutes. DIEA (24 uL, 0.144 mmol) was then added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 1 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 56 (white solid, 34 mg, 90% yield) was obtained. MS: 1051.35 [M+H] +
[0288] Step 2: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaazaazaalkane-14-yl-1-aminocyclopropanecarboxylate
[0289] Compound 56 (34 mg, 0.032 mmol) was placed in a 25 mL single-necked vial. Methanol (3 mL) and Pd / C (15 mg) were added. The air in the reaction flask was replaced three times with a full hydrogen balloon while stirring. The reaction was allowed to proceed at room temperature for 3 h. LCMS confirmed the complete reaction of the starting compound 56. After filtration and spin drying, the crude product, compound 57 (white solid, 30 mg, yield 101%), was obtained. MS: 917.22 [M+H] +
[0290] Step 3: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaazacyclohexan-14-yl-1-(((S((9H-fluoro-9-methoxy)carbonyl)amino)-5-(tert-butoxy)-5-oxopentanamido)cyclopropane-1-carboxylate
[0291] Compound 57 (30 mg, 0.033 mmol), Fmoc-L-glutamic acid-5-tert-butyl ester (14 mg, 0.033 mmol), and HATU (15 mg, 0.04 mmol) were added to N,N-dimethylformamide (4 mL) and stirred at room temperature for 10 minutes. DIEA (22 uL, 0.132 mmol) was then added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 57 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 58 (white solid, 28 mg, 64% yield) was obtained. MS: 662.84 [M+2H] 2+ / 2
[0292] Step 4: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradec-14-yl 1-((S)-2-amino-5-(tert-butoxy)-5-oxopentanamido)cyclopropane-1-carboxylate
[0293] Compound 58 (28 mg, 0.021 mmol) was placed in a 25 mL single-necked flask, and N,N-dimethylformamide (5 mL) and piperidine (0.5 mL) were added. The reaction was allowed to proceed at room temperature for 10 minutes. LCMS confirmed the complete reaction of the starting compound 6. The reaction solution was then dried to give the crude product, compound 59 (colorless oil, 35 mg, 151% yield). MS: 1102.44 [M+H] +
[0294] Step 5: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazacan-14-yl 1-((2S)-5-(tert-butoxy)-2-(3-(tert-butoxycarbonyl)amino)-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanamido)-5-oxopentanamido)cyclopropane-1-carboxylate
[0295] Compound 47 (13 mg, 0.032 mmol) and HATU (15 mg, 0.038 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. Compound 59 (35 mg, 0.032 mmol) and DIEA (22 uL, 0.128 mmol) were then added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 59 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 60 (white solid, 25 mg, 43.6% yield) was obtained. MS: 854.94 [M+2H] 2+ / 2
[0296] Step 6: Synthesis of (4S)-4-(3-amino-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoyl)-5-((1-((10S,13R,14R)-10-benzyl-14-((S)-1-((3R,4S,5S)-4-(S)-2-((S(2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-13-methyl-9,12-dioxy-2,5,15-trioxa-8,11-diazadecanoyl)cyclopropyl)amino)-5-oxopentanoic acid
[0297] Compound 60 (25 mg, 0.017 mmol) was placed in a 25 mL single-necked vial. Dichloromethane (2 mL) and HCl / 1,4-dioxane solution (1 mL, 4 M) were added and allowed to react at room temperature for 1 h. LCMS monitoring confirmed the complete reaction of compound 60. After spin drying, the crude product, compound 61 (white solid, 23 mg, 102% yield) was obtained. MS: 676.82 [M+2H] 2+ / 2
[0298] Step 7: (37S)-37-((1-((10S,13R,14R)-10-benzyl-14-((S)-1-((3R,4S,5S)-4-(S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl) Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-3,3-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,35-trioxo-7,10,13,16,19,22,25,28-octaoxo-4,32,36-triazatetradecane-40-oic acid)-1-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-3,3-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,35-trioxo-7,10,13,16,19,22,25,28-octaoxo-4,32,36-triazatetradecane-40-oic acid)
[0299] Maleimidooctaethylene glycol propionic acid (5 mg, 0.007 mmol) and compound 61 (9 mg, 0.007 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. DIEA (5 uL, 0.027 mmol) was then added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 61 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound DL-13 was obtained (white solid, 1 mg, 7% yield). MS: 1927.27 [M+H] +
[0300] 1 H NMR(400MHz,D2O)δ7.31–7.16(m,5H),6.79(s,2H),4.49(m,1H),4.04(m,2H),3.77–3 .46(m,56H),3.46–3.35(m,5H),3.34–3.20(m,12H),3.14(m,2H),3.08(m,6H),2.84(m ,8H),2.63(m,2H),2.43(m,7H),2.21(m,2H),1.98(m,1H),1.76(m,1H),1.51(m,2H), 1.24(m,1H),1.12(m,3H),1.06–0.98(m,2H),0.94(m,11H),0.86(m,6H),0.78(m,4H).
[0301] Example 14: Preparation of Compound DL-14
[0302] Step 1: Synthesis of 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoic acid
[0303] Compound 3-Fmoc-aminoglutaric acid (100.1 mg, 0.271 mmol) and HATU (103.0 mg, 0.271 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. DIEA (134 μL, 0.813 mmol) and meglumine (52.9 mg, 0.271 mmol) were then added and stirred at room temperature for 1 hour. The reaction was monitored by LCMS. The reaction solution was diluted 2-fold and washed with water (15 mL) and saturated brine (15 mL) in sequence. The organic phases were extracted twice, combined, dried over anhydrous sodium sulfate, and the solvent evaporated under reduced pressure. The product was purified by preparative liquid phase separation using acetonitrile / water. Compound 62 (white solid, 148.1 mg, 100% yield) was obtained. MS: 548.68 [M+H] + .
[0304] Step 2: (2S)-2-(3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoamide)-5-(tert-butoxy)-5-oxopentanoic acid
[0305] Compound L-glutamic acid-5-tert-butyl ester (148.1 mg, 0.271 mmol) and HATU (103.0 mg, 0.271 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. DIEA (134 μL, 0.813 mmol) and compound 62 (55.1 mg, 0.271 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 62, which was considered complete. The reaction solution was diluted 2-fold and washed sequentially with water (15 mL) and saturated brine (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The product was purified by preparative liquid phase separation using acetonitrile / water. Compound 63 (white solid, 166.6 mg, 84.0% yield) was obtained. MS: 733.20 [M+H] + .
[0306] Step 3: Synthesis of (2S)-2-(3-amino-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoamide)-5-(tert-butoxy)-5-oxopentanoic acid
[0307] Compound 63 (166.6 mg, 0.228 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 mL) and allowed to react at room temperature for 15 minutes. LCMS confirmed the complete reaction of compound 5. The reaction solution was distilled under reduced pressure to remove the solvent, and then washed repeatedly with 50 x 3 mL of petroleum ether to remove impurities, yielding compound 64 (white solid, 116.1 mg, yield 100.1%). MS: 511.62 [M+H] + .
[0308] Step 4: Synthesis of (2S)-2-(3-(tert-butoxy)-3-oxopropyl)-38-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-6-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,8,36-trioxo-11,14,17,20,23,26,29,32-octaoxo-3,7,35-triazaoctacotrienoic acid
[0309] Maleimidooctaethylene glycol propionic acid (45.0 mg, 0.0759 mmol) and HATU (28.9 mg, 0.0759 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (38 μL, 0.228 mmol) and compound 64 (38.7 mg, 0.0759 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 64, which was considered complete. The reaction solution was diluted 2-fold and washed sequentially with water (15 mL) and saturated brine (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The product was purified by preparative liquid phase separation using acetonitrile / water. Compound 65 (white solid, 40.0 mg, 48.6% yield) was obtained. MS: 543.28 [M+2H] 2+ / 2.
[0310] Step 5: (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradecane-14-yl)-(2S,5S)-2-benzyl-5-(3-(tert-butoxy)-3-oxopropyl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradecane-14-yl)- Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-9-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,7,11,11,39-tetraoxo-14,17,20,23,26,29,33,35-octaoxo-3,6,10,38-tetraazatetraoctanoate
[0311] Compound 65 (15.0 mg, 0.0138 mmol) and HATU (5.3 mg, 0.0138 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (7 μL, 0.0415 mmol) and compound 66 (13.6 mg, 0.0138 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 65, which was considered complete. The reaction solution was diluted 2-fold and washed sequentially with water (15 mL) and saturated brine (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The product was purified by preparative liquid phase separation using acetonitrile / water. Compound 67 (white solid, 8.5 mg, 30.0% yield) was obtained. MS: 1024.46 [M+2H] 2+ / 2.
[0312] Step 6: (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradecane-14-yl)-(2S,5S)-2-benzyl-5-(3-(tert-butoxy)-3-oxopropyl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradecane-14-yl)- Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-9-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,7,11,11,39-tetraoxo-14,17,20,23,26,29,33,35-octaoxo-3,6,10,38-tetraazatetraoctanoate
[0313] Compound 67 (10.2 mg, 0.0052 mmol) was added to dichloromethane (1.0 mL) and trifluoroacetic acid (0.5 mL). The reaction was allowed to proceed at room temperature for 30 minutes. LCMS monitored the complete reaction of the starting compound 67. The solvent was removed by distillation under reduced pressure, and the product was purified by preparative liquid phase separation using acetonitrile / water. Compound DL-14 was obtained (white solid, 0.48 mg, 5.8% yield). MS: 1991.36 [M+H] + .
[0314] 1 H NMR(400MHz,D2O)δ7.36–7.05(m,13H),4.29(s,2H),4.20(s,3H),4.01(s,4H),3.70(m,7H),3.66–3.52(m,29H ),3.48(m,4H),3.33(m,4H),3.29(s,2H),3.24(m,7H),3.16(m,3H),3.10(s,2H),3.07(s,2H),3.05–3.00(m,2H ),2.87(m,10H),2.57(m,6H),2.42(m,10H),2.32–2.10(m,7H),1.75(m,5H),1.67–1.45(m,6H),1.31(m,8H),1. 11(d,J=6.8Hz,2H),1.04(d,J=6.7Hz,2H),1.00(d,J=6.7Hz,1H),0.98–0.89(m,9H),0.87(m,5H),0.78(m,5H).
[0315] Example 15: Preparation of Compound DL-15
[0316] Step 1: Synthesis of 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoic acid
[0317] Compound 3-Fmoc-aminoglutaric acid (100.1 mg, 0.271 mmol) and HATU (103.0 mg, 0.271 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. DIEA (134 μL, 0.813 mmol) and compound meglumine (52.9 mg, 0.271 mmol) were then added and stirred at room temperature for 1 hour. The reaction was monitored by LCMS. The reaction solution was diluted 2-fold and washed with water (15 mL) and saturated brine (15 mL) in sequence. The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The product was purified by preparative liquid phase separation using acetonitrile / water. Compound 62 (white solid, 148.1 mg, 100% yield) was obtained. MS: 548.68 [M+H] + .
[0318] Step 2: Synthesis of (2S)-2-(3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoamide)-5-(tert-butoxy)-5-oxopentanoic acid
[0319] Compound 62 (148.1 mg, 0.271 mmol) and HATU (103.0 mg, 0.271 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. DIEA (134 μL, 0.813 mmol) and compound L-glutamic acid-5-tert-butyl ester (55.1 mg, 0.271 mmol) were then added and stirred at room temperature for 1 hour. LCMS monitoring of the reaction was completed. The reaction solution was diluted 2-fold and washed with water (15 mL) and saturated brine (15 mL) in sequence. The organic phases were extracted twice and combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The product was purified by preparative liquid phase separation using acetonitrile / water. Compound 63 (white solid, 166.6 mg, yield 84.0%) was prepared. MS: 733.20 [M+H] + .
[0320] Step 3: Synthesis of (2S)-2-(3-amino-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoamide)-5-(tert-butoxy)-5-oxopentanoic acid
[0321] Compound 63 (166.6 mg, 0.228 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 mL) and allowed to react at room temperature for 15 minutes. LCMS confirmed the complete reaction of compound 5. The reaction solution was distilled under reduced pressure to remove the solvent, and then washed repeatedly with 50 x 3 mL of petroleum ether to remove impurities, yielding compound 64 (white solid, 116.1 mg, yield 100.1%). MS: 511.62 [M+H] + .
[0322] Step 4: Synthesis of (2S)-2-(3-(tert-butoxy)-3-oxopropyl)-38-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-6-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,8,36-trioxo-11,14,17,20,23,26,29,32-octaoxo-3,7,35-triazaoctacotrienoic acid
[0323] Maleimidooctaethylene glycol propionic acid (45.0 mg, 0.0759 mmol) and HATU (28.9 mg, 0.0759 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (38 μL, 0.228 mmol) and compound 64 (38.7 mg, 0.0759 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 64, which was considered complete. The reaction solution was diluted 2-fold and washed sequentially with water (15 mL) and saturated brine (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The product was purified by preparative liquid phase separation using acetonitrile / water. Compound 65 (white solid, 40.0 mg, 48.6% yield) was obtained. MS: 543.28 [M+2H] 2+ .
[0324] Step 5: (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradecane-14-yl (2S,5S)-5-(3-(tert-butoxy)-3-oxopropyl)-2-(tert-butoxymethyl)-41-( Synthesis of 2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-9-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,7,11,11,3,39-tetraoxo-14,17,20,23,26,29,32,35-octaoxo-3,35-octaoxy-6,,10,38-tetraazabenzene tetracarboxylate
[0325] Compound 65 (15.0 mg, 0.0138 mmol) and HATU (5.3 mg, 0.0138 mmol) were added to N,N-dimethylformamide (2 mL) and stirred at room temperature for 10 minutes. DIEA (7 μL, 0.0415 mmol) and compound 68 (13.5 mg, 0.0138 mmol) were then added and stirred at room temperature for 1 hour. LCMS showed that the reaction solution contained less than 3% of compound 68, which was considered complete. The reaction solution was diluted 2-fold and washed sequentially with water (15 mL) and saturated brine (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The product was purified by preparative liquid phase separation using acetonitrile / water. Compound 69 (white solid, 14.0 mg, 49.5% yield) was obtained. MS: 1022.48 [M+2H] 2+ .
[0326] Step 6: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-18-hydroxy-4-methyl-5,8,16-trioxy-2,12,15-trioxo-6,9-diazaoctadec-17-yl)amino Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3,3-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,31,35-trioxy-7,10,13,16,19,22,25,28-octaoxy-4,32,3,6-triazatetradecane-40-oic acid)
[0327] Compound 69 (14.0 mg, 0.0069 mmol) was added to dichloromethane (1.0 mL) and trifluoroacetic acid (0.5 mL). The reaction was allowed to proceed at room temperature for 30 minutes. LCMS monitored the complete reaction of the starting compound 69. The solvent was removed by distillation under reduced pressure, and the product was purified by preparative liquid phase separation using acetonitrile / water. Compound DL-15 was obtained (white solid, 0.48 mg, 5.8% yield). MS: 1931.26 [M+H] + .
[0328] 1 H NMR(400MHz,D2O)δ7.30–7.13(m,5H),6.79(s,2H),4.60(m,1H),4.48(s,1H),4.36(s,1H),4.29–4.14(m,3H),4.08–3.86(m,3 H),3.71(m,6H),3.67(m,5H),3.61(m,21H),3.60–3.55(m,8H),3.55–3.51(m,2H),3.48(m,3H),3.45–3.32(m,4H),3.30(s,2H) ,3.25(m,7H),3.20–3.13(m,2H),3.10(m,3H),3.05(d,J=4.7Hz,2H),2.92–2.79(m,8H),2.61(m,3H),2.55–2.32(m,9H),2.25( s,4H),1.97(s,3H),1.80(m,3H),1.59(s,6H),1.24(m,4H),1.12(s,1H),1.03(m,3H),0.95(m,10H),0.87(m,8H),0.78(s,6H).
[0329] Example 16: Preparation of Compound DL-16
[0330] Step 1: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazapyridin-14-yl-2-((tert-butoxycarbonyl)amino)-2-methylpropanoate
[0331] N-tert-Butyloxycarbonyl-2-methylalanine (12 mg, 0.06 mmol) and HATU (27 mg, 0.07 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 10 minutes. DIEA (40 μL, 0.24 mmol) was then added and stirred at room temperature for 10 minutes. Finally, compound 1 (50 mg, 0.06 mmol) was added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 1 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 70 was obtained (white solid, 44 mg, 72% yield). MS: 1019.35 [M+H] +
[0332] Step 2: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaazaalkan-14-yl-2-amino-2-methylpropanoate
[0333] Compound 70 (44 mg, 0.04 mmol) was placed in a 25 mL single-necked vial. Dichloromethane (3 mL) and HCl / 1,4-dioxane solution (1 mL, 4 M) were added and allowed to react at room temperature for 1 h. LCMS monitoring confirmed the complete reaction of compound 70. After spin drying, the crude product, compound 71 (white solid, 43 mg, 110% yield) was obtained. MS: 919.23 [M+H] +
[0334] Step 3: Synthesis of tert-butyl (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16-trioxy-2,12,15-trioxa-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate
[0335] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (20 mg, 0.047 mmol) and HATU (22 mg, 0.056 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 10 minutes. DIEA (24 uL, 0.188 mmol) was then added and stirred at room temperature for 10 minutes. Finally, compound 71 (43 mg, 0.047 mmol) was added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 71 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 72 (white solid, 41 mg, 66% yield) was obtained. MS: 663.85 [M+2H] 2+ / 2
[0336] Step 4: Synthesis of tert-butyl (S)-4-amino-5-(((3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16-trioxo-2,12,15-trioxo-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate
[0337] Compound 72 (41 mg, 0.031 mmol) was placed in a 25 mL single-necked flask, and N,N-dimethylformamide (5 mL) and piperidine (0.5 mL) were added. The mixture was allowed to react at room temperature for 10 min. LCMS monitored the complete reaction of compound 72. The reaction solution was spin-dried, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 73 was obtained (white solid, 31 mg, 91% yield). MS: 1104.45 [M+H] +
[0338] Step 5: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaazepan-14-yl(9S)-9-(3-(tert-butoxy)-3-oxopropyl)-1-(9H-fluoro-9-yl)-12,12-dimethyl-5-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,7,10-trioxy-4,11-triazatridec-13-oic acid
[0339] Compound 62 (23 mg, 0.042 mmol) and HATU (19 mg, 0.05 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. Compound 73 (31 mg, 0.028 mmol) and DIEA (18 uL, 0.112 mmol) were then added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 73 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 74 (white solid, 31 mg, 67.8% yield) was obtained. MS: 817.0 [M+2H] 2+ / 2
[0340] Step 6: Synthesis of tert-butyl (4S)-4-(3-amino-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoyl)-5-(((3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16-trioxy-2,12,15-trioxa-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate
[0341] Compound 74 (31 mg, 0.019 mmol) was placed in a 25 mL single-necked flask, and N,N-dimethylformamide (5 mL) and piperidine (0.5 mL) were added. The mixture was allowed to react at room temperature for 10 min. LCMS monitored the complete reaction of compound 74. The reaction solution was spin-dried, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 75 was obtained as a white solid, 23 mg, yield 86%. MS: 705.88 [M+2H] 2+ / 2
[0342] Step 7: (3R,4R,7S)-7-Benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazepin-14-yl (5S)-5-(3-(tert-butoxy)- Synthesis of 3-oxopropyl)-41-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-2,2-dimethyl-9-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,7,11,39-tetraoxo-14,17,20,23,26,29,32,32,35-octaoxo-3,6,10,38-tetraazabenzene tetracarboxylate
[0343] Compound 75 (23 mg, 0.016 mmol), maleimidooctaethylene glycol propionic acid (12 mg, 0.016 mmol), and HATU (7.3 mg, 0.019 mmol) were added to N,N-dimethylformamide (3 mL) and stirred evenly. DIEA (8 uL, 0.064 mmol) was then added and stirred at room temperature for 3 hours. LCMS showed that the reaction solution contained less than 3% of compound 75, which was considered complete. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 76 (white solid, 17 mg, 53.5% yield) was obtained. MS: 993.2 [M+2H] 2+ / 2
[0344] Step 8: (37S)-37-(((3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazo Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-3,3-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,35-trioxo-7,10,13,16,19,22,25,28-octaoxo-4,32,36-triazatetradecane-40-oic acid)
[0345] Compound 76 (17 mg, 0.009 mmol) was placed in a 25 mL single-necked flask, and dichloromethane (3 mL) and trifluoroacetic acid (1 mL) were added. The reaction was allowed to proceed at room temperature for 1 h. LCMS confirmed the complete reaction of compound 12. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound DL-16 was obtained (white solid, 8.9 mg, 53.9% yield). MS: 1929.29 [M+H] +
[0346] 1 H NMR(400MHz,D2O)δ7.34–7.11(m,5H),6.79(s,2H),4.64–4.55(m,4H),4. 56–4.45(m,2H),4.27–4.12(m,4H),4.05–3.99(m,1H),3.98–3.87(m,2H), 3.80–3.67(m,5H),3.68–3.52(m,29H),3.52–3.46(m,3H),3.45–3.38(m, 2H),3.39–3.32(m,2H),3.30(s,2H),3.28–3.21(m,6H),3.20–3.00(m,8H) ,2.95–2.75(m,9H),2.73–2.56(m,4H),2.55–2.33(m,10H),2.32–2.14(m ,4H),2.09–1.92(m,4H),1.81(d,J=42.7Hz,5H),1.65–1.45(m,4H),1.40( s,6H),1.32–1.19(m,3H),1.14–1.08(m,2H),1.05(d,J=6.7Hz,2H),1.03– 0.98(m,2H),0.99–0.90(m,9H),0.90–0.82(m,5H),0.78(t,J=7.3Hz,4H).
[0347] Example 17: Preparation of Compound DL-17
[0348] Step 1: Synthesis of 2-(2-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S()-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methyl-2-methylpropionamido)-3-phenylpropionamidoethoxy)ethyl N2-((((9H-fluoren-9-yl)methoxy)carbonyl)-N6-(tert-butoxycarbonyl)-L-lysine salt
[0349] Compound N-Fmoc-N'-Boc-L-lysine (21 mg, 0.045 mmol) and HATU (20 mg, 0.053 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 10 minutes. DIEA (30 μL, 0.18 mmol) was then added and stirred at room temperature for 10 minutes. Finally, compound 1 (40 mg, 0.045 mmol) was added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 1 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 76 (white solid, 46 mg, 75.4% yield) was obtained. MS: 678.37 [M+2H] 2+ / 2
[0350] Step 2: 2-(2-((S)-2-((2R,3R)-3-(S)-1-((3R,4S,5S)-4-((S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methyl-2-methylpropionamido)-3-phenylpropionamidoethoxy)ethyl N6-(tert-butoxycarbonyl)-L-lysine
[0351] Compound 76 (46 mg, 0.034 mmol) was placed in a 25 mL single-necked flask, and N,N-dimethylformamide (5 mL) and piperidine (0.5 mL) were added. The mixture was allowed to react at room temperature for 10 min. LCMS monitored the complete reaction of compound 76. The reaction solution was spin-dried, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 77 was obtained as a white solid, 36 mg, yield 93.5%. MS: 567.26 [M+2H] 2+ / 2
[0352] Step 3: 2-(2-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamide)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-methoxy-2-methylpropionamido)-3-phenylpropionamido)ethoxy)ethyl N 2-(3-(((((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentananoyl)-N 6-(tert-butoxycarbonyl)-1-lysyl-alanine
[0353] Compound 62 (26 mg, 0.048 mmol) and HATU (24 mg, 0.063 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 10 minutes. DIEA (21 uL, 0.126 mmol) was then added and stirred at room temperature for 10 minutes. Finally, compound 77 (36 mg, 0.032 mmol) was added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 77 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 78 (white solid, 26 mg, 48.9% yield) was obtained. MS: 831.52 [M+2H] 2+ / 2
[0354] Step 4: 2-(2-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methyl-2-methylpropionamido)-3-phenylpropionamidoethoxy)ethyl N2-(3-amino-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoyl)-N6-(tert-butoxycarbonyl)-L-lysyl-L-alanine
[0355] Compound 78 (26 mg, 0.016 mmol) was placed in a 25 mL single-necked flask, and N,N-dimethylformamide (5 mL) and piperidine (0.5 mL) were added. The mixture was allowed to react at room temperature for 10 min. LCMS monitored the complete reaction of compound 78. The reaction solution was spin-dried, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 79 was obtained as a white solid, 7.6 mg, yield 33%. MS: 720.4 [M+2H] 2+ / 2
[0356] Step 5: 2-(2-((S)-2-((2R,3R)-3-(S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanamido)ethoxy)ethyl N6-(tert-butoxycarbonyl) Synthesis of -N2-(1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-33-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31-dioxy-7,10,13,16,19,22,25,28-octaoxy-4,32-diazapentaazacyclopentane-35-yl)-L-lysine-alanine
[0357] Maleimidooctaethylene glycol propionic acid (3.76 mg, 0.006 mmol) and HATU (3 mg, 0.008 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 10 minutes. DIEA (3.5 uL, 0.021 mmol) was then added and stirred at room temperature for 10 minutes. Finally, compound 79 (7.6 mg, 0.005 mmol) was added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed less than 3% of compound 79 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 80 (white solid, 5 mg, 49.7% yield) was obtained. MS: 1007.72 [M+2H] 2+ / 2
[0358] Step 6: 2-(2-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)ethoxy)ethyl(1 Synthesis of -(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-33-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31-dioxy-7,10,13,16,19,22,25,28-octaoxy-4,32-diazadentate tricyclo-35-oxy)-L-lysyl-L-alanine
[0359] Compound 80 (5 mg, 0.0025 mmol) was placed in a 25 mL single-necked vial. Dichloromethane (3 mL) and a hydrochloric acid / 1,4-dioxane solution (1 mL, 4 M) were added. The mixture was allowed to react at room temperature for 1 h. LCMS confirmed the complete reaction of compound 80. After spin drying, the crude product, compound DL-17 (white solid, 2 mg, 41.8% yield) was obtained. MS: 1914.32 [M+H] +
[0360] 1 H NMR(400MHz,D2O)δ7.32–7.16(m,5H),6.79(s,2H),4.66–4.46(m,2H),4.37–4.15(m,2H),4.14–3.82(m,1 H),3.78–3.65(m,9H),3.64–3.51(m,45H),3.51–3.34(m,9H),3.32–3.20(m,11H),3.16–3.03(m,6H),2.94 –2.80(m,10H),2.69–2.60(m,2H),2.51–2.35(m,8H),2.32–1.94(m,2H),1.85–1.68(m,2H),1.66–1.42(m ,6H),1.41–1.20(m,7H),1.14–0.98(m,3H),0.99–0.90(m,11H),0.90–0.82(m,6H),0.78(t,J=7.3Hz,5H).
[0361] Example 18: Preparation of Compound DL-18
[0362] Step 1: Synthesis of 2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethyl(tert-butoxycarbonyl)valine salt
[0363] Compound Boc-valine (53 mg, 0.242 mmol) and HATU (92 mg, 0.0.242 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 20 minutes. DIEA (134 uL, 0.808 mmol) and compound 80 (100 mg, 0.202 mmol) were then added and stirred at room temperature for 24 hours. LCMS showed a small amount of compound 80 remaining in the reaction solution, indicating the reaction was complete. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 81 (white solid, 167 mg, yield 119.3%) was obtained. MS: 693.74 [M+H] +
[0364] Step 2: Synthesis of 2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethyl valine
[0365] Compound 81 (167 mg, 0.241 mmol) was placed in a 25 mL single-necked flask. Dichloromethane (5 mL) and 1 mL of 4 M hydrochloric acid and ethyl acetate solution were added. The mixture was allowed to react at room temperature for 1 h. LCMS confirmed the complete reaction of compound 81. After spin drying, a yellow solid was obtained. Compound 82 (yellow solid, 142 mg, 92% yield) was obtained. MS: 593.62 [M+H] +
[0366] Step 3: Synthesis of tert-butyl (4S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-ylamino)-5-oxopentanoate
[0367] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (102 mg, 0.239 mmol) and HATU (110 mg, 0.287 mmol) were added to dichloromethane (10 mL) and stirred at room temperature for 20 minutes. DIEA (158 μL, 0.956 mmol) and compound 82 (142 mg, 0.239 mmol) were then added and stirred at room temperature for 5 hours. LCMS showed a small amount of compound 82 remaining in the reaction solution, indicating the completion of the reaction. The solvent was evaporated under reduced pressure, and the crude product was purified by silica gel column chromatography using 3% MeOH / DCM. Compound 83 was obtained (white solid, 72 mg, 30% yield). MS: 1001.09 [M+H] +
[0368] Step 4: Synthesis of tert-butyl (4S)-4-amino-5-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-ylamino)-5-oxopentanoate
[0369] Compound 83 (72 mg, 0.072 mmol) was placed in a 25 mL single-necked flask, and N,N-dimethylformamide (5 mL) and piperidine (0.5 mL) were added. The mixture was allowed to react at room temperature for 10 minutes. LCMS confirmed the complete reaction of compound 83. After spin drying, the crude product was purified by preparative liquid chromatography to afford compound 84 (white solid, 34 mg, yield 60.7%). MS: 778.85 [M+H] +
[0370] Step 5: Synthesis of 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((2S)-5-(tert-butoxy)-1-((1-(2-((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-yl)aminoamino)-1,5-dioxopentan-2-yl)amino)-5-oxopentanic acid
[0371] Compound 3-Fmoc-aminoglutaric acid (19.4 mg, 0.0524 mmol) and HATU (24 mg, 0.063 mmol) were added to N,N-dimethylformamide (4 mL) and stirred at room temperature for 20 minutes. DIEA (35 uL, 0.21 mmol) and compound 84 (34 mg, 0.0437 mmol) were then added and stirred at room temperature for 4 hours. The reaction was considered complete when LCMS showed less than 3% of compound 84 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid chromatography to obtain compound 85 (white solid, 21 mg, 42.9% yield). MS: 1130.21 [M+H] +
[0372] Step 6: Synthesis of 3-amino-5-(((2S)-5-(tert-butoxy)-1-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-yl)aminoamino)-1,5-dioxopentan-2-ylamino)-5-oxopentanic acid
[0373] Compound 85 (21 mg, 0.019 mmol) was placed in a 25 mL single-necked vial, and N,N-dimethylformamide (5 mL) and piperidine (0.5 mL) were added. The mixture was allowed to react at room temperature for 10 min. LCMS confirmed the complete reaction of compound 85. After spin drying, the crude product was purified by preparative liquid chromatography to afford compound 86 (white solid, 16 mg, 92.9% yield). MS: 907.96 [M+H] +
[0374] Step 7: (8S,17S,18R,19R,20R)-8-(3-(tert-Butoxy)-3-oxopropyl)-1-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[3',4':6,7]nazo[1,2-b]quinolin-1-yl) Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azabenzenetricarboxylate (amino)-17,18,19,20,21-pentahydroxy-5-isopropyl-15-methyl-1,4,7,10,14-pentaoxo-3-oxo-6,9,15-triazacyclohexan-12-yl)-1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azabenzenetricarboxylate
[0375] Maleimidooctaethylene glycol propionic acid (12.4 mg, 0.021 mmol) and HATU (9.6 mg, 0.025 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 20 minutes. DIEA (14 uL, 0.084 mmol) and compound 86 (16 mg, 0.018 mmol) were then added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed that the reaction solution contained less than 3% of compound 86. Compound 87 was obtained and was used directly in the next step without purification.
[0376] HATU (9.6 mg, 0.025 mmol) was then added and the reaction was stirred at room temperature for 5 minutes. DIEA (7 uL, 0.041 mmol) and meglumine (6.1 mg, 0.031 mmol) were then added and stirred at room temperature for 3 hours. LCMS showed that the reaction solution contained less than 3% of compound 86, which was considered complete. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid chromatography to obtain compound 88 (white solid, 11 mg, 36.8% yield). MS: 742.28 [M+2H] 2+ / 2
[0377] Step 8: (37S)-1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-37-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline Synthesis of 3-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,35-trioxo-7,10,13,16,19,22,25,28-octaoxo-4,32,36-triazatetracarboxylic acid)
[0378] Compound 88 (11 mg, 0.007 mmol) was placed in a 25 mL single-necked flask. Dichloromethane (5 mL) and a hydrochloric acid-ethyl acetate solution (1 mL, 4 M) were added and allowed to react at room temperature for 1 h. LCMS monitored the complete reaction of compound 88. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by HPLC. Compound DL-18 was obtained as a white solid, 10 mg, 89.3% yield. MS: 1603.68 [M+H] +
[0379] 1H NMR (400MHz, DMSO-d6) δ8.02(s,1H),7.87(d,J=10.9Hz,1H),7.38(s,1H),7.07(s,1H),5.83(s,1H),5.68–5.60(m,1H),5.50(s,2H),5.31(m 2H),4.63(m,2H),4.45–4.25(m,3H),4.17–4.05(m,1H),3.87–3.78(m, 1H),3.70–3.13(m,42H),2.47(s,3H),2.42–2.17(m,9H),1.97–1.85(m ,3H),1.81–1.67(m,2H),1.61–1.50(m,2H),1.45–1.39(m,2H),1.39–1 .32(m,5H),1.30(s,6H),1.27–1.21(m,3H),1.00(m,5H),0.93(m,4H).
[0380] Example 19: Preparation of Compound DL-19
[0381] Step 1: Synthesis of 2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethyl(tert-butoxycarbonyl)valine salt
[0382] Compound Boc-valine (53 mg, 0.242 mmol) and HATU (92 mg, 0.0.242 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 20 minutes. DIEA (134 uL, 0.808 mmol) and compound 80 (100 mg, 0.202 mmol) were then added and stirred at room temperature for 24 hours. LCMS showed a trace amount of compound 80 remaining in the reaction solution, indicating the reaction was complete. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 81 (white solid, 167 mg, yield 119.3%) was obtained. MS: 693.74 [M+H] +
[0383] Step 2: Synthesis of 2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethyl valine
[0384] Compound 81 (167 mg, 0.241 mmol) was placed in a 25 mL single-necked flask. Dichloromethane (5 mL) and a hydrochloric acid-ethyl acetate solution (1 mL, 4 M) were added. The mixture was allowed to react at room temperature for 1 h. LCMS confirmed the complete reaction of compound 81. After spin drying, compound 82 (142 mg, 93% yield) was obtained as a yellow solid. MS: 593.62 [M+H] +
[0385] Step 3: Synthesis of tert-butyl (4S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-ylamino)-5-oxopentanoate
[0386] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (102 mg, 0.239 mmol) and HATU (110 mg, 0.287 mmol) were added to dichloromethane (10 mL) and stirred at room temperature for 20 minutes. DIEA (158 uL, 0.956 mmol) and compound 82 (142 mg, 0.239 mmol) were then added and stirred at room temperature for 5 hours. LCMS showed a small amount of compound 82 remaining in the reaction solution and a large impurity peak, indicating the reaction was complete. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by silica gel column chromatography using 3% MeOH / DCM. Compound 83 was obtained (white solid, 72 mg, 30% yield). MS: 1001.09 [M+H] +
[0387] Step 4: Synthesis of tert-butyl (4S)-4-amino-5-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-ylamino)-5-oxopentanoate
[0388] Compound 83 (72 mg, 0.072 mmol) was placed in a 25 mL single-necked flask, and N,N-dimethylformamide (5 mL) and piperidine (0.5 mL) were added. The mixture was allowed to react at room temperature for 10 minutes. LCMS confirmed the complete reaction of compound 83. After spin drying, the crude product was purified by preparative liquid chromatography to afford compound 84 (white solid, 34 mg, yield 60.7%). MS: 778.85 [M+H] +
[0389] Step 5: Synthesis of 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((2S)-5-(tert-butoxy)-1-((1-(2-((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-yl)aminoamino)-1,5-dioxopentan-2-yl)amino)-5-oxopentanic acid
[0390] Compound 3-Fmoc-aminoglutaric acid (19.4 mg, 0.0524 mmol) and HATU (24 mg, 0.063 mmol) were added to N,N-dimethylformamide (4 mL) and stirred at room temperature for 20 minutes. DIEA (35 uL, 0.21 mmol) and compound 84 (34 mg, 0.0437 mmol) were then added and stirred at room temperature for 4 hours. The reaction was considered complete when LCMS showed less than 3% of compound 84 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid chromatography to obtain compound 85 (white solid, 21 mg, 42.9% yield). MS: 1130.21 [M+H] +
[0391] Step 6: Synthesis of 3-amino-5-(((2S)-5-(tert-butoxy)-1-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-yl)aminoamino)-1,5-dioxopentan-2-ylamino)-5-oxopentanic acid
[0392] Compound 85 (21 mg, 0.019 mmol) was placed in a 25 mL single-necked vial, and N,N-dimethylformamide (5 mL) and piperidine (0.5 mL) were added. The mixture was allowed to react at room temperature for 10 min. LCMS confirmed the complete reaction of compound 85. After spin drying, the crude product was purified by preparative liquid chromatography to afford compound 86 (white solid, 16 mg, 92.9% yield). MS: 907.96 [M+H] +
[0393] Step 7: (18S)-18-(3-(tert-Butoxy)-3-oxopropyl)-25-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino) Synthesis of 1-(2,5-dioxo-2,25-dihydro-1H-pyrrol-1-yl)-21-isopropyl-12,16,19,22,25-pentaoxo-2,5,8,23-tetraoxa-11,17,20-triazapentacarbonyl-14-yl)-1-(2,5-dioxo-2,25-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azatrioxan-31-ol
[0394] Maleimidooctaethylene glycol propionic acid (6.5 mg, 0.011 mmol) and HATU (5.0 mg, 0.013 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. DIEA (7.3 uL, 0.044 mmol) and compound 86 (10 mg, 0.011 mmol) were then added and stirred at room temperature for 3 hours. The reaction was considered complete when LCMS showed that the reaction solution contained less than 3% of compound 86. Compound 87 was obtained and was used directly in the next step without purification.
[0395] HATU (5.0 mg, 0.013 mmol) was then added and the reaction was stirred at room temperature for 5 minutes. DIEA (4 uL, 0.024 mmol) and methyl-triethylene glycol-amine (2.7 mg, 0.017 mmol) were then added and stirred at room temperature for 3 hours. LCMS showed that the reaction solution contained less than 3% of compound 87, which was considered complete. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid chromatography to obtain compound 89 (white solid, 10 mg, 55.6% yield). MS: 814.88 [M+2H] 2+ / 2
[0396] Step 8: (37S)-1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-37-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,13,15-hexahydro-1H,12H-benzo[3',4':6,7]indolizine[1,2-b]quinoline Synthesis of 1,2-dioxo-3,3-dioxo-4,3-dioxo-5,6-dioxathiazolyl-1,3-oxo-6-oxo-7-oxo-1,3-oxo-1 ...
[0397] Compound 89 (10 mg, 0.006 mmol) was placed in a 25 mL single-necked vial. Dichloromethane (1 mL) and HCl / 1,4-dioxane solution (1 mL, 4 M) were added and allowed to react at room temperature for 1 h. LCMS monitored the complete reaction of the starting compound 14. The solvent was evaporated under reduced pressure, and the crude product was separated and purified by HPLC. Compound DL-19 was obtained (white solid, 2 mg, 21.2% yield). MS: 1571.66 [M+H] +
[0398] 1 H NMR(400MHz,D2O)δ7.24(m,2H),6.76(m,2H),5.54(s,2H),5.42(m,1H),5.28(d,J=16.3Hz,1H),4.98(d, J=18.9Hz,1H),4.77(s,3H),4.40–4.27(m,1H),4.11(s,1H),3.88(s,1H),3.67(m,2H),3.64–3.59(m,10 H),3.59(m,4H),3.57(m,6H),3.56–3.53(m,8H),3.51(s,3H),3.46(m,3H),3.27(m,3H),3.22(m,4H),3. 03(m,5H),2.35(m,10H),2.29(s,1H),2.22–2.01(m,9H),1.85(m,3H),1.64(m,4H),0.88–0.69(m,10H).
[0399] Example 20: Preparation of Compound DL-20
[0400] Step 1: Synthesis of 2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethyl(tert-butoxycarbonyl)valine salt
[0401] Compound Boc-valine (53 mg, 0.242 mmol) and HATU (92 mg, 0.0.242 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 20 minutes. DIEA (134 uL, 0.808 mmol) and compound 80 (100 mg, 0.202 mmol) were then added and stirred at room temperature for 24 hours. LCMS showed a small amount of compound 80 remaining in the reaction solution, indicating the reaction was complete. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 81 (white solid, 167 mg, yield 119.3%) was obtained. MS: 693.74 [M+H] +
[0402] Step 2: Synthesis of 2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethyl valine
[0403] Compound 81 (167 mg, 0.241 mmol) was placed in a 25 mL single-necked flask. Dichloromethane (5 mL) and 1 mL of 4 M hydrochloric acid and ethyl acetate solution were added. The mixture was allowed to react at room temperature for 1 h. LCMS confirmed the complete reaction of compound 81. After spin drying, a yellow solid was obtained. Compound 82 (yellow solid, 142 mg, 93% yield) was obtained. MS: 593.62 [M+H] +
[0404] Step 4: Synthesis of tert-butyl (4S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-ylamino)-5-oxopentanoate
[0405] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (102 mg, 0.239 mmol) and HATU (110 mg, 0.287 mmol) were added to dichloromethane (10 mL) and stirred at room temperature for 20 minutes. DIEA (158 uL, 0.956 mmol) and compound 82 (142 mg, 0.239 mmol) were then added and stirred at room temperature for 5 hours. LCMS showed a small amount of compound 82 remaining in the reaction solution and a large impurity peak, indicating the reaction was complete. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by silica gel column chromatography using 3% MeOH / DCM. Compound 83 was obtained (white solid, 72 mg, 30% yield). MS: 1001.09 [M+H] +
[0406] Step 5: Synthesis of tert-butyl (4S)-4-amino-5-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-ylamino)-5-oxopentanoate
[0407] Compound 83 (72 mg, 0.072 mmol) was placed in a 25 mL single-necked flask, and N,N-dimethylformamide (5 mL) and piperidine (0.5 mL) were added. The mixture was allowed to react at room temperature for 10 minutes. LCMS confirmed the complete reaction of compound 83. After spin drying, the crude product was purified by preparative liquid chromatography to afford compound 84 (white solid, 34 mg, yield 60.7%). MS: 778.85 [M+H] +
[0408] Step 6: Synthesis of 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((2S)-5-(tert-butoxy)-1-((1-(2-((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-yl)aminoamino)-1,5-dioxopentan-2-yl)amino)-5-oxopentanic acid
[0409] Compound 3-Fmoc-aminoglutaric acid (19.4 mg, 0.0524 mmol) and HATU (24 mg, 0.063 mmol) were added to N,N-dimethylformamide (4 mL) and stirred at room temperature for 20 minutes. DIEA (35 uL, 0.21 mmol) and compound 84 (34 mg, 0.0437 mmol) were then added and stirred at room temperature for 4 hours. The reaction was considered complete when LCMS showed less than 3% of compound 84 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid chromatography to obtain compound 85 (white solid, 21 mg, 42.9% yield). MS: 1130.21 [M+H] +
[0410] Step 7: Synthesis of 3-amino-5-(((2S)-5-(tert-butoxy)-1-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-yl)aminoamino)-1,5-dioxopentan-2-ylamino)-5-oxopentanic acid
[0411] Compound 85 (21 mg, 0.019 mmol) was placed in a 25 mL single-necked vial, and N,N-dimethylformamide (5 mL) and piperidine (0.5 mL) were added. The mixture was allowed to react at room temperature for 10 min. LCMS confirmed the complete reaction of compound 85. After spin drying, the crude product was purified by preparative liquid chromatography to afford compound 86 (white solid, 16 mg, 92.9% yield). MS: 907.96 [M+H] +
[0412] Step 8: 2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethyl (2R,5S)-5-(3-(tert-butyloxy)-3-oxopropyl)-41-(2,5- Synthesis of dioxo-2,5-dihydro-1H-pyrrol-1-yl)-2-isopropyl-4,7,11,39-tetraoxo-9-(2-oxo-2-(((3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)ethyl)-14,17,20,23,26,29,32,35-octaoxa-3,6,10,38-tetraazabenzene tetracarboxylate
[0413] Maleimidooctaethylene glycol propionic acid (7 mg, 0.011 mmol) and HATU (5.0 mg, 0.013 mmol) were added to N,N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, and then DIEA (7.3 uL, 0.044 mmol) and compound 86 (10 mg, 0.011 mmol) were added and stirred at room temperature for 3 hours. LCMS showed that the reaction solution contained less than 3% of compound 86, which was considered to be the end of the reaction. Compound 87 was directly used in the next step without purification.
[0414] HATU (5.0 mg, 0.013 mmol) was then added and the reaction was stirred at room temperature for 5 minutes. DIEA (4 uL, 0.024 mmol) and D-glucosamine hydrochloride (5 mg, 0.022 mmol) were then added and stirred at room temperature for 3 hours. LCMS showed that the reaction solution contained less than 3% of compound 87, which was considered complete. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid chromatography to obtain compound 90 (white solid, 7 mg, 38.9% yield). MS: 822.37 [M+2H] 2+ / 2
[0415] Step 9: (37S)-1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-37-(((R)-1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-3,3,9,10,13,15-hexahydro-1H,12H)-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino Synthesis of 7,10,13,16,19,22,25,28-octaoxa-4,32,36-triazatetracan-40-oic acid (2-oxoethoxy)-3-methyl-1-oxobutan-2-yl)carbamoyl)-3,31,35-trioxy-33-(2-oxo-2-(((3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)ethyl)
[0416] Compound 90 (7 mg, 0.004 mmol) was placed in a 25 mL single-necked flask. Dichloromethane (1 mL) and HCl / 1,4-dioxane solution (1 mL, 4 M) were added and allowed to react at room temperature for 1 h. LCMS monitored the complete reaction of compound 90. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was separated and purified by HPLC. Compound DL-20 was obtained (white solid, 1 mg, 14.8% yield). MS: 1587.64 [M+H] +
[0417] 1H NMR (400MHz, D2O) δ8.37(s,1H),7.86(s,1H),7.26(s,2H),6.76(d,J=1.9Hz,2H),5.54(s,2H),5.43(d,J=1 6.5Hz,2H),5.29(m,2H),5.14–4.92(m,4H),4.76(s,3H),4.38(m,2H),4.11(m,2H),3.97–3.64(m,6H),3.6 4–3.49(m,16H),3.46(s,3H),3.35(s,2H),3.22(m,2H),3.04(s,3H),2.94(s,1H),2.78(s,1H),2.37(m,7H ),2.17(s,3H),2.05(m,4H),1.93–1.76(m,3H),1.76–1.52(m,3H),1.46(m,1H),1.24(m,4H),0.82(m,10H).
[0418] Example 21: Preparation of Compound DL-21
[0419] Step 1: Synthesis of 2-(2-(tert-butoxy)-2-oxoethoxy)ethyl(((9H-fluoren-9-yl)methoxy)carbonyl)-L-valine
[0420] Compound Fmoc-valine (97 mg, 0.286 mmol) and HATU (130 mg, 0.342 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 10 minutes. DIEA (94 uL, 0.568 mmol) and compound 91 (50 mg, 0.284 mmol) were then added and stirred at room temperature for 24 hours. LCMS showed a small amount of compound 91 remaining in the reaction solution, indicating the reaction was complete. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 92 was obtained as a white solid, 110 mg, 77.8% yield. MS: 498.59 [M+H]+.
[0421] Step 2: Synthesis of (S)-1-(9H-fluoren-9-yl)-5-isopropyl-3,6-dioxo-2,7,10-trioxo-4-azadodecane-12-oic acid
[0422] Compound 92 (110 mg, 0.221 mmol) was placed in a 25 mL single-necked vial. Dichloromethane (5 mL) and a hydrochloric acid / 1,4-dioxane solution (2 mL, 4 M) were added. The mixture was allowed to react at room temperature for 1 hour. LCMS confirmed the complete reaction of compound 92. After spin drying, a yellow solid was obtained. Compound 93 (yellow solid, 70 mg, 71.7% yield) was obtained. MS: 442.48 [M+H]+.
[0423] Step 3: Synthesis of 2-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13, 15-hexahydro-1H,12H-benzo[d]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)ethyl(((9H-fluoren-9-yl)methoxy)carbonyl)-L-valine
[0424] Compound 93 (70 mg, 0.159 mmol) and HATU (74 mg, 0.195 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 10 minutes. Compound 94 (84 mg, 0.158 mmol) and DIEA (200 μL, 1.209 mmol) were then added and stirred at room temperature for 4 hours. LCMS showed a small amount of compound 94 remaining in the reaction solution, indicating the completion of the reaction. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid phase separation using acetonitrile / water. Compound 95 was obtained as a solid oil, 140 mg, 102.5% yield. MS: 859.92 [M+H]+.
[0425] Step 4: Synthesis of 2-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[d]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)ethyl L-valine
[0426] Compound 95 (140 mg, 0.163 mmol) was placed in a 25 mL single-necked vial. N,N-dimethylformamide (3 mL) and DEA (0.5 mL) were added and reacted at room temperature for 20 min. LCMS confirmed the complete reaction of compound 95. After spin drying, the crude product was purified by preparative liquid chromatography to afford compound 96 (white solid, 86 mg, 82.9% yield). MS: 637.68 [M+H]+.
[0427] Step 5: 2-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[d]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)ethyl(2S,5S)-5-(3-(tert-butyloxy)-3-oxopropyl)- Synthesis of 41-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-2-isopropyl-9-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,7,11,39-tetraoxo-14,17,20,23,26,29,32,32,35-octaoxo-3,6,10,38-tetradecanoic acid azaphenyl ester
[0428] Compound 65 (23 mg, 0.021 mmol) and HATU (11 mg, 0.029 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature for 10 minutes. Compound 96 (15 mg, 0.023 mmol) and DIEA (15 μL, 0.093 mmol) were then added and stirred at room temperature for 4 hours. The reaction was considered complete when LCMS showed less than 3% of compound 96 in the reaction solution. The solvent was evaporated under reduced pressure, and the crude product was purified by preparative liquid chromatography to obtain compound 97 (white solid, 16 mg, 44.7% yield). MS: 852.42 [M+2H]2+ / 2.
[0429] Step 6: (37S)-1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-37-((S)-1-)2-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[d]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-1 Synthesis of [3-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,35-trioxo-7,10,13,16,19,22,25,28-octaoxa-4,32,36-triazatetracarbonane-40-carboxylic acid]]-3-methyl-1-oxobutan-2-yl)carbamoyl)-3,3-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,35-trioxo-7,10,13,16,19,22,25,28-octaoxa-4,32,36-triazatetracarbonane-40-carboxylic acid]]
[0430] Compound 97 (16 mg, 0.0094 mmol) was placed in a 25 mL single-necked flask, and dichloromethane (2.5 mL) and trifluoroacetic acid (2.5 mL) were added. The reaction was allowed to react at room temperature for 1 hour. LCMS monitored the complete reaction of compound 97. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was separated and purified by HPLC. The solvent was lyophilized to obtain compound DL-21 (white solid, 5 mg, yield 32.3%). MS: 824.37 [M+2H]2+ / 2
[0431] 1 H NMR (400MHz, DMSO-d6) δ8.41(d,J=8.8Hz,1H),8.13–8.03(m,1H),8.02–7.96(m,1H),7.87(m,1H),7.82–7.75(m,1H),7.31(s,1H) ),6.99(s,1H),6.51(s,1H),5.42(s,1H),5.21(s,1H),4.89(s,1H),4.70(s,1H),4.46(m,2H),4.40–4.22(m,5H),4.16(m,1H),4. 06(m,2H),3.73(m,3H),3.63–3.43(m,35H),3.36(m,5H),3.17(m,4H),2.99(m,2H),2.80(d,J=2.5Hz,2H),2.40(s,3H),2.36–2.2 9(m,3H),2.30–2.14(m,6H),1.99–1.91(m,1H),1.85(m,3H),1.74–1.62(m,1H),0.91–0.82(m,4H),0.78(dd,J=11.5,6.8Hz,5H).
[0432] Preparation example:
[0433] General steps Antibody reduction:
[0434] To a PBS buffer solution of trastuzumab (0.05 M PBS aqueous solution at pH = 7.0; 2 mg, 0.014 μmol) was added a prepared aqueous solution of the reducing agent tris(2-carboxyethyl)phosphine (4-10 eq). The mixture was placed in a water bath or metal bath under inert gas protection and oscillated at 25-37° C. for 0.5-2.0 hours. After stopping the reaction, the reaction solution was cooled to room temperature for subsequent coupling reactions.
[0435] ADC synthesis:
[0436] An aqueous solution of compound DL-1 (0.388 mL, 1 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution. The mixture was placed on a shaker under inert gas protection and allowed to react at room temperature for 1.5 hours. The reaction was then stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution. The mixture was placed on a shaker under inert gas protection and allowed to react at room temperature for 1.0 hour. The reaction was then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH = 7.0) to obtain a PBS buffer solution of the coupled product ADC-1 (5.8 mg / mL, 0.33 mL). The solution was stored frozen at -80°C. The average DAR value was calculated by reduction-reverse phase chromatography, with a value of n = 5.4.
[0437] An aqueous solution of compound DL-2 (0.096 mL, 4 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution. The mixture was placed on a shaker under inert gas protection and allowed to react at room temperature for 1.5 hours. The reaction was then stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution. The mixture was placed on a shaker under inert gas protection and allowed to react at room temperature for 1.0 hour. The reaction was then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH = 7.0) to obtain a PBS buffer solution of the conjugated product ADC-2 (11.9 mg / mL, 0.15 mL). The solution was stored frozen at -80°C. The average DAR value (n = 7.7) was calculated by reduction-reverse phase chromatography.
[0438] An aqueous solution of compound DL-3 (0.126 mL, 3 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution. The mixture was placed on a shaker under inert gas protection and allowed to react at room temperature for 1.5 hours. The reaction was then stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution. The mixture was placed on a shaker under inert gas protection and allowed to react at room temperature for 1.0 hour. The reaction was then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH = 7.0) to obtain a PBS buffer solution of the conjugated product ADC-3 (12.4 mg / mL, 0.15 mL). The solution was stored frozen at -80°C. The DAR value was calculated by reduction-reverse phase chromatography to be approximately n = 6.5.
[0439] An aqueous solution of compound DL-4 (0.126 mL, 3.0 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution. The mixture was shaken at room temperature for 1.5 hours under inert gas protection on a shaker. The reaction was then stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution. The mixture was shaken at room temperature for 1.0 hour under inert gas protection on a shaker. The reaction was then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH = 7.0) to obtain a PBS buffer solution of the conjugated product ADC-4 (6.5 mg / mL, 0.2 mL). The product was stored frozen at -80°C. The DAR value was calculated by reduction-reverse phase chromatography to be approximately n = 7.0.
[0440] An aqueous solution of compound DL-5 (0.188 mL, 2.0 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution. The mixture was shaken at room temperature for 1.5 hours under inert gas protection on a shaker. The reaction was then stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution. The mixture was shaken at room temperature for 1.0 hour under inert gas protection on a shaker. The reaction was then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH = 7.0) to obtain a PBS buffer solution of the conjugated product ADC-5 (4.6 mg / mL, 0.3 mL). The product was stored frozen at -80°C. The DAR value was calculated by reduction-reverse phase chromatography to be approximately n = 4.2.
[0441] An aqueous solution of compound DL-6 (0.382 mL, 1.0 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution. The mixture was shaken at room temperature for 1.5 hours under inert gas protection on a shaker. The reaction was then stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution. The mixture was shaken at room temperature for 1.0 hour under inert gas protection on a shaker. The reaction was then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH = 7.0) to obtain a PBS buffer solution of the conjugated product ADC-6 (5.9 mg / mL, 0.33 mL). The product was stored frozen at -80°C. The DAR value was calculated by reduction-reverse phase chromatography to be approximately n = 5.8.
[0442] An aqueous solution of compound DL-7 (0.098 mL, 4.0 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution. The mixture was placed on a shaker under inert gas protection and allowed to react at room temperature for 1.5 hours. The reaction was then stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution. The mixture was placed on a shaker under inert gas protection and allowed to react at room temperature for 1.0 hour. The reaction was then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH = 7.0) to obtain a PBS buffer solution of the conjugated product ADC-7 (7.9 mg / mL, 0.23 mL). The product was stored frozen at -80°C. The DAR value was calculated by reduction-reverse phase chromatography to be approximately n = 7.1.
[0443] An aqueous solution of compound DL-8 (0.110 mL, 3.5 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution. The mixture was shaken at room temperature for 1.5 hours under inert gas protection on a shaker. The reaction was then stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution. The mixture was shaken at room temperature for 1.0 hour under inert gas protection on a shaker. The reaction was then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH = 7.0) to obtain a PBS buffer solution of the conjugated product ADC-8 (8.2 mg / mL, 0.25 mL). The solution was stored frozen at -80°C. The DAR value was calculated by reduction-reverse phase chromatography to be approximately n = 7.3.
[0444] An aqueous solution of compound DL-9 (0.092 mL, 4.1 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution. The mixture was shaken at room temperature for 1.5 hours under inert gas protection on a shaker. The reaction was then stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution. The mixture was shaken at room temperature for 0.3 hours under inert gas protection on a shaker. The reaction was then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH 7.0) to obtain a PBS buffer solution of the conjugated product ADC-9 (4.96 mg / mL, 0.36 mL). The solution was stored frozen at -80°C. The DAR value was calculated by reduction-reverse phase chromatography to be approximately n = 7.1.
[0445] An aqueous solution of compound DL-10 (0.098 mL, 4.0 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution. The mixture was shaken at room temperature for 1.5 hours under inert gas protection on a shaker. The reaction was then stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution. The mixture was shaken at room temperature for 0.3 hours under inert gas protection on a shaker. The reaction was then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH 7.0) to obtain a PBS buffer solution of the conjugated product ADC-10 (5.88 mg / mL, 0.35 mL). The solution was stored frozen at -80°C. The DAR value was calculated by reduction-reverse phase chromatography to be approximately 6.5.
[0446] An aqueous solution of compound DL-11 (0.096 mL, 4.0 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution. The mixture was shaken at room temperature for 1.5 hours under inert gas protection on a shaker. The reaction was then stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution. The mixture was shaken at room temperature for 0.3 hours under inert gas protection on a shaker. The reaction was then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH = 7.0) to obtain a PBS buffer solution of the conjugated product ADC-11 (7.72 mg / mL, 0.24 mL). The product was stored frozen at -80°C. The DAR value was calculated by reduction-reverse phase chromatography to be approximately n = 5.3.
[0447] An aqueous solution of compound DL-12 (0.097 mL, 4.0 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution. The mixture was shaken at room temperature for 1.5 hours under inert gas protection on a shaker. The reaction was then stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution. The mixture was shaken at room temperature for 0.3 hours under inert gas protection on a shaker. The reaction was then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH = 7.0) to obtain a PBS buffer solution of the conjugated product ADC-12 (6.12 mg / mL, 0.305 mL). The solution was stored frozen at -80°C. The DAR value was calculated by reduction-reverse phase chromatography to be approximately n = 5.0.
[0448] An aqueous solution of compound DL-13 (0.096 mL, 4.0 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution. The mixture was shaken at room temperature for 1.5 hours under inert gas protection on a shaker. The reaction was then stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution. The mixture was shaken at room temperature for 0.3 hours under inert gas protection on a shaker. The reaction was then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH = 7.0) to obtain a PBS buffer solution of the conjugated product ADC-13 (5.68 mg / mL, 0.32 mL). The solution was stored frozen at -80°C. The DAR value was calculated by reduction-reverse phase chromatography to be approximately n = 4.2.
[0449] An aqueous solution of compound DL-14 (0.100 mL, 4.0 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution. The mixture was shaken at room temperature for 1.5 hours under inert gas protection on a shaker. The reaction was then stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution. The mixture was shaken at room temperature for 0.3 hours under inert gas protection on a shaker. The reaction was then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH = 7.0) to obtain a PBS buffer solution of the conjugated product ADC-14 (4.72 mg / mL, 0.33 mL). The solution was stored frozen at -80°C. The DAR value was calculated by reduction-reverse phase chromatography to be approximately n = 5.6.
[0450] An aqueous solution of compound DL-15 (0.096 mL, 4.0 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution and placed on a shaker under inert gas protection. The reaction was shaken at room temperature for 1.5 hours, and then the reaction was stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution. The reaction was shaken at room temperature for 0.3 hours under inert gas protection and then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH = 7.0) to obtain a PBS buffer solution of the conjugated product ADC-15 (5.31 mg / mL, 0.32 mL) and stored frozen at -80°C. The DAR value was calculated by reduction-reverse phase chromatography to be approximately n = 7.4.
[0451] An aqueous solution of compound DL-17 (0.096 mL, 4.0 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution. The mixture was placed on a shaker under inert gas protection and allowed to react at room temperature for 1.5 hours. The reaction was then stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution. The mixture was placed on a shaker under inert gas protection and allowed to react at room temperature for 0.3 hours. The reaction was then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH = 7.0) to obtain a PBS buffer solution of the conjugated product ADC-16 (6.19 mg / mL, 0.3 mL). The solution was stored frozen at -80°C. The DAR value was calculated by reduction-reverse phase chromatography to be approximately n = 4.5.
[0452] An aqueous solution of compound DL-18 (0.091 mL, 3.5 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution, placed on a shaker under inert gas protection, and allowed to react at room temperature for 1.5 hours. The reaction was then stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution, placed on a shaker under inert gas protection, and allowed to react at room temperature for 1.0 hour. The reaction was then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH = 7.0) to obtain a PBS buffer solution of the conjugated product ADC-16 (11.2 mg / mL, 0.15 mL), which was stored frozen at -80°C. The DAR value calculated by reduction-reverse phase chromatography was approximately 7.45, with a calculated average DAR value of n = 7.45.
[0453] An aqueous solution of compound DL-19 (0.157 mL, 2.0 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution, placed on a shaker under inert gas protection, and allowed to react at room temperature for 1.5 hours. The reaction was then stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution, placed on a shaker under inert gas protection, and allowed to react at room temperature for 1.0 hour. The reaction was then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH = 7.0) to obtain a PBS buffer solution of the conjugated product ADC-17 (5.2 mg / mL, 0.3 mL), which was stored frozen at -80°C. The DAR value calculated by reduction-reverse phase chromatography was approximately 6.9, with an average DAR value of n = 6.9.
[0454] An aqueous solution of compound DL-20 (0.317 mL, 1.0 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution. The mixture was placed on a shaker under inert gas protection and allowed to react at room temperature for 1.5 hours. The reaction was then stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution. The mixture was placed on a shaker under inert gas protection and allowed to react at room temperature for 1.0 hour. The reaction was then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH = 7.0) to obtain a PBS buffer solution of the conjugated product ADC-19 (8.5 mg / mL, 0.2 mL). The solution was stored frozen at -80°C. The DAR value was calculated by reduction-reverse phase chromatography, with an average DAR value of n = 7.3.
[0455] An aqueous solution of compound DL-21 (0.082 mL, 4.0 mg / mL, 0.2 μmol) was added to the above 0.208 mL antibody reaction solution. The mixture was placed on a shaker under inert gas and allowed to react at 25°C for 1.5 hours. The reaction was then stopped. An aqueous solution of compound NAC (0.004 mL, 100 mM, 0.4 μmol) was added to the reaction solution. Ar gas was then applied and the mixture was placed on a shaker. The reaction was then allowed to react at 25°C for 0.3 hours. The reaction was then stopped. The reaction solution was ultrafiltered using an Amicon Ultra-15 30 kD ultrafiltration tube at 12,000 rpm at 10°C using 0.05 M PBS buffer (pH 7.0) to obtain a PBS buffer solution of the conjugated product ADC-20 (5.1 mg / mL, 0.32 mL). The solution was stored frozen at -80°C. The DAR value was calculated by reduction-reverse phase chromatography, with an average DAR value of n = 7.1.
[0456] Among them, the specific analysis and detection method of ADC samples is as follows:
[0457] 1.HIC detection
[0458] Prepare a solution of 25 mM phosphate buffer and 1.2 M ammonium sulfate. Take an appropriate amount of sample and dissolve and dilute with solvent in a 1:1 ratio. Use a butyl-bonded polymethacrylate matrix as the filler (TOSOH TSKgel Butyl-NPR 2.5 μm 4.6 x 35 mm or equivalent performance column). Use a solution of 25 mM phosphate buffer and 1.2 M ammonium sulfate as mobile phase A; 25 mM phosphate buffer-isopropanol (80-20) as mobile phase B. Elution should be performed using a mobile phase gradient (B: 0-100%). Detection wavelength: 280 nm. Maintain column temperature at room temperature. Flow rate: 0.5 ml / min. Injection volume: 50 μl.
[0459] 2.SEC detection
[0460] Take an appropriate amount of this product, dissolve and dilute it with solvent to make about 1-2 mg of sample per 1 ml, use diol-bonded gel as the filler (Waters Xbridge Premier Protein SEC 7.8*300mm or equivalent performance column); use 20mM phosphate buffer and 150mM sodium chloride solution as the mobile phase; the detection wavelength is 280nm; the column temperature is room temperature; the flow rate is 0.8ml per minute; the injection volume is 10μl.
[0461] 3. Reverse phase detection
[0462] Prepare mobile phase A: 0.5‰ TFA in acetonitrile, mobile phase B: 0.5‰ TFA in water. Add 1μL of 10mM DTT (20μL) to the sample to be tested and allow to react at room temperature for 30 minutes for reduction. Use an Aglient PLRP-S 1000A 5μm column (50 x 2.1mm) and perform gradient elution (mobile phase A: 0-100%) at 70°C.
[0463] Test Example 1: In vitro inhibition test of tumor cell proliferation by ADC drugs
[0464] 1. Experimental Purpose
[0465] The purpose of this experiment was to test the in vitro proliferation inhibitory activity of the ADC drugs of the present invention against tumor cells with different expression levels. The proliferation inhibitory activity was tested on NCI-N87 cells, SK-BR-3 cells, JIMT-1 cells, and MCF7 cells. After treating the cells with different concentrations of the ADC drugs in vitro and culturing them for 6 days, cell viability was measured using the CTG (CellTiter-Glo Luminescent Cell Viability Assay, Promega, Cat. No. G7571) reagent. The inhibitory effect of the ADC drugs on tumor cell proliferation was evaluated based on the IC50 value.
[0466] 2. Experimental methods
[0467] 1) Cell culture
[0468] NCI-N87 cells (Cell Bank, Chinese Academy of Sciences, Catalog No. TCHu130) and SK-BR-3 cells (Cell Bank, Chinese Academy of Sciences, Catalog No. TCHu225) were cultured with 1640 complete medium containing 15% FBS and McCoy's 5A complete medium containing 10% FBS, respectively. JIMT-1 cells (Nanjing Kebai Biological, CBP60378) and MCF7 cells (Cell Bank, Chinese Academy of Sciences, Catalog No. TCHu74) were cultured with DMEM complete medium containing 10% FBS.
[0469] 2) Cell preparation
[0470] Wash the cells at stable passage twice with 5-10 mL of DPBS, then digest them with 1-2 mL of 0.25% Trypsin-EDTA. Once digestion is complete, add 2.5-3 times the volume of trypsin-containing complete medium to the culture flask to terminate digestion. Transfer the digested cells to a centrifuge tube and centrifuge at 1000 rpm for 5 minutes. After centrifugation, discard the supernatant and resuspend in complete medium. Gently pipette to evenly distribute the cells before counting.
[0471] 3)Planning
[0472] Dilute NCI-N87 cells to 5.55 × 104 cells / mL using complete culture medium, add 90 μL per well to the designated positions of a 96-well white opaque plate, and fill the edge wells with sterile DPBS at a filling volume of 200 μL / well. Culture in a 37°C, 5% CO2 incubator overnight to allow attachment.
[0473] 4) Sample preparation
[0474] Pre-dilute the ADC samples to 1350 nM in complete medium. Perform a 5-fold serial dilution in complete medium for a total of nine steps. Add 10 μL of diluted ADC sample to the designated positions of a 96-well plate at each concentration, with two replicates per well. Add complete medium to the cells in column 11 to serve as a control for normal cell growth.
[0475] 5) Cultivation
[0476] After adding, tap the plate several times around the sides to mix the sample and culture medium evenly, and then place the plate in a 37°C, 5% CO2 cell culture incubator for 6 days.
[0477] 6) Cell viability assay
[0478] After culturing for 6 days, After the reagent is thawed and the cell culture plate is placed at room temperature for 30 minutes, 50 μL is added to each well. The cell plate is shaken on a shaker for 2 minutes and then incubated at room temperature for 10 minutes to stabilize the luminescent signal.
[0479] 7) Plate reading
[0480] The luminescence chemiluminescence value was read using a BMG Omega microplate reader. The results are shown in Table 1 below.
[0481] 3. Experimental results
[0482] Table 1
[0483] It can be seen that the ADC drugs of the present invention have obvious proliferation inhibitory activity on four tumor cells, NCI-N87, SK-BR-3, JIMT-1 and MCF7, and the inhibitory effect of some ADC drugs is greater than that of the positive control DS8201, especially in inhibiting the proliferation of JIMT-1 and MCF7 breast cancer tumor cells.
[0484] Test Example 2: Evaluation of the efficacy of ADC drugs in JIMT-1 tumor-bearing mice
[0485] 1. Experimental Purpose
[0486] The anti-tumor effect of the ADC drug of the present invention was evaluated in a female NOD / SCID mouse animal model with subcutaneous xenografts of human breast cancer JIMT-1 cell line.
[0487] 2. Experimental methods
[0488] NOD / SCID mice were subcutaneously inoculated with human JIMT-1 breast cancer cells to establish a subcutaneous human breast cancer model. Four groups of six mice were divided into a vehicle control group, a test drug group containing ADC-2 (MPA-4) at 3 mg / kg, a test drug group containing ADC-16 (MPD-4) at 3 mg / kg, and a test drug group containing DS8201 at 3 mg / kg. Each group received a single intravenous injection on the day of grouping. Efficacy was evaluated based on relative tumor inhibition (TGI), and safety was assessed based on changes in animal body weight and mortality.
[0489] After tumor cell inoculation, routine monitoring includes tumor growth and the effect of treatment on the normal behavior of the animals, including the activity of the experimental animals, food and water intake, weight gain or loss, eyes, fur and other abnormalities. Clinical symptoms observed during the experiment are recorded in the original data. After the start of drug administration, the weight and tumor size of the mice are measured twice a week. Tumor volume calculation formula: Tumor volume (mm 3 )=1 / 2×(a×b2 (where a represents the major diameter and b represents the minor diameter). Data were collected using StudyDirector™ (version 3.1.399.19, supplied by Studylog System, Inc.), including tumor major and minor diameter measurements and animal body weights. Raw data were directly imported into the software after measurements using a balance and vernier calipers, and any changes in the data were recorded. All procedures, including dosing, tumor measurement, and body weight, were performed in a biosafety cabinet or clean bench.
[0490] Tumor proliferation rate (T / C (%)): T / C = TmTV / CmTV × 100%; TmTV: average of the treatment group; CmTV: average of the control group; Tumor inhibition rate (TGI (%)): TGI = (1-T / C) × 100%; where T / C% is the tumor proliferation rate, which is the percentage value of the relative tumor volume (or body weight) of the treatment group and the control group at a certain time point.
[0491] 3. Experimental results
[0492] As shown in Figure 1, the average tumor volume of mice in the vehicle control group was 906.20 mm on day 28. 3 The average tumor volume of the ADC-2 (MPA-4) 3mg / kg test drug group on day 28 was 15.87mm 3 The relative tumor inhibition rate (TGI) was 98.29%, which was statistically significantly different from the control group (p<0.001). The complete tumor inhibition rate was 3 / 6. The average tumor volume of the ADC-16 (MPD-4) 3mg / kg test drug group on day 28 was 423.93mm 3 The relative tumor inhibition rate (TGI) was 52.91%, which was statistically significantly different from the control group (p<0.001). The average tumor volume of the DS8201 3mg / kg test drug group on day 28 was 893.02mm 3 The relative tumor inhibition rate TGI (%) was 9.31%, which had no statistically significant difference compared with the control group (p>0.05).
[0493] The ADC-2 (MPA-4) 3 mg / kg, ADC-16 (MPD-4) 3 mg / kg, and DS8201 3 mg / kg test drug groups did not cause weight loss in mice (Figure 2), and no animals died in any treatment group, indicating that the treatment was well tolerated.
Claims
1. A compound of formula (I) or an isotope-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, PLD (I) in, P has the following structure: m and n are each independently selected from any integer from 0 to 12; X1 is selected from a bond, a C1-C6 alkylene group, an imino group, an ester group, an amide group, a carbonate group, a carbamate group, a sulfone group, a sulfonamide group, a ketone group, a urea group or a phosphate group; X2 is selected from a bond, nitrogen, oxygen, sulfur, phosphorus, a C1-C6 alkylene group, an imino group, an ester group, an amide group, a carbonate group, a carbamate group, a sulfone group, a sulfonamide group, a ketone group, a urea group or a phosphate group; L has the following structure: n1 and n2 are each independently selected from any integer from 0 to 6; R1 is selected from a hydrophilic group; R2 and R3 are each independently selected from H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, or R2 and R3 together with the carbon atoms to which they are attached form a C3-C6 cycloalkyl, wherein one or more hydrogen atoms in the C1-C6 alkyl, C1-C6 haloalkyl or C3-C6 cycloalkyl are optionally substituted with halogen, hydroxyl, cyano, amino, C1-C3 alkyl or phenyl; R4 is selected from the R group in the α-amino acid general formula R-CH(NH2)COOH; R5 is selected from a bond or -Y1-R6-Y2-, wherein Y1 is a bond, -NH- or -O-, Y2 is -NH- or -C=O-, R6 Selected from -(CH2) z -、-(OCH2) z -、-(CH2O) z -、-(CH2CH2O) z -、-(OCH2CH2) z -, C3-C6 cycloalkyl or a covalently linked combination thereof, z is selected from any integer from 0 to 6; and D is a toxin molecule or other equivalent.
2. The compound of formula (I) according to claim 1, wherein the hydrophilic group has at least three ether bonds and / or hydroxyl groups consisting of oxygen-containing groups, preferably, the hydrophilic group has any one of the following structures:
3. formula (I) compound according to claim 1, wherein R2 and R3 are each independently selected from H, F, Cl, methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or R2 and R3 form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl together with the carbon atom to which they are connected, wherein one or more hydrogen atoms in said methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl are optionally replaced by halogen, hydroxyl, cyano, amino, C1-C3 alkyl or phenyl.
4. The compound of formula (I) according to claim 1, wherein R4 is selected from the R group of glutamic acid, aspartic acid, lysine, arginine, histidine, alanine, valine or tryptophan; preferably glutamic acid, aspartic acid or lysine.
5. The compound of formula (I) according to claim 1, wherein R5 is selected from a bond, -O-(CH2) z -NH-, -(OCH2) z -NH-, -(OCH2) z -CO-, -(OCH2CH2) z -CO- or -(OCH2CH2) z -NH-, z is selected from any integer from 1 to 3; preferably a bond, -(OCH2) z -CO-, -(OCH2CH2) z -CO- or -(OCH2CH2) z -NH-.
6. The compound of formula (I) according to claim 1, wherein the toxin molecule is a microtubule disruptor, an anti-mitotic inhibitor or a DNA damaging drug.
7. The compound of formula (I) according to claim 1, wherein the toxin molecule is a maytansine, auristatin, paclitaxel, anthramycin, calicheamicin, duocarmycin, camptothecin or amanitin toxin molecule.
8. The compound of formula (I) according to claim 1, wherein the toxin molecule is an auristatin F derivative having the following structure:
9. The compound of formula (I) according to claim 1, wherein the toxin molecule is an exitecan analogue having the following structure:
10. A conjugate comprising a compound of formula (I) or an isotope-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt or solvate thereof as a conjugation precursor of the conjugate according to any one of claims 1 to 9. The conjugate according to claim 10 , wherein the conjugate further comprises a targeting moiety.
12. The conjugate according to claim 11, wherein the targeting moiety forms a free thiol group by reduction of the interchain disulfide bond for coupling with the maleimide group of the compound of formula (I).
13. The conjugate according to claim 11, wherein the DAR value is any integer or decimal between 1 and 10, preferably between 4 and 8.
14. The conjugate according to claim 10, wherein the targeting moiety is selected from antibodies, synthetic functionalized antibodies, peptides or other targeting ligands.
15. The conjugate of claim 14, wherein the targeting moiety is an antibody or a synthetic functionalized antibody specific for an antigen overexpressed in cancer cells.
16. The conjugate of claim 15, wherein the targeting moiety is an antibody or synthetic functionalized antibody specific for an antigen selected from the group consisting of HER2, EGFR, Claudin18.2, c-MET, Nectin-4, ROR1, GPNMB, CD56, TACSTD2 (TROP2), CEACAM5, folate receptor-a, mesothelin, ENPP3, guanylate cyclase C, SLC44A4, NaPi2b, CD70, mucin 1, STEAP1, connexin 4, 5T4, SLTRK6, SC-16, LIV-1, P-cadherin, PSMA, fibronectin extradomain B, endothelin receptor ETB, tenascin c, collagen IV, VEGFR2, periostin, CD30, CD79b, CD19, CD22, CD138, CD37, CD33, CD74, CD19 and CD98.
17. The conjugate of claim 16, wherein the targeting moiety is trastuzumab or synthetically functionalized trastuzumab.
18. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 9 or an isotope-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt thereof, or a conjugate according to any one of claims 10 to 17; and a pharmaceutically acceptable carrier.
19. The pharmaceutical composition according to claim 18, wherein the dosage form is selected from tablets, capsules, granules, powders, syrups, inhalants or injections.
20. Use of a compound of formula (I) or an isotope-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9, or a conjugate according to any one of claims 10 to 17 in the preparation of a medicament for treating or preventing cancer in a subject in need thereof.
21. The use according to claim 20, wherein the cancer is a HER2 positive cancer.
22. The use according to claim 21, wherein the HER2-positive cancer is a cancer in which HER2 is overexpressed.
23. The use according to claim 22, wherein the cancer is breast cancer.
24. The use according to claim 20, wherein the drug is an antibody-drug conjugate.
Citation Information
Patent Citations
Novel antibody conjugates and uses thereof
CN105164159A
PEGylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
CN105764503A
Albumin-binding prodrugs of auristatin e derivatives
CN111712511A
Anti-her2 biparatopic antibody-drug conjugates and methods of use
CN112020519A
Linker, antibody-drug conjugate including same, and use thereof
CN112543752A
